



Published in final edited form as:

Nat Genet. 2019 March ; 51(3): 452–469. doi:10.1038/s41588-018-0334-2.

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

***CORRESPONDING AUTHORS:** Prof. Kari North, Department of Epidemiology, University of North Carolina at Chapel Hill, 137 East Franklin Street, Suite 306, Chapel Hill, NC 27514, Prof. Cecilia M Lindgren, The Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, United Kingdom, celi@well.ox.ac.uk.

[†]These authors contributed equally to this work.

[‡]These authors jointly supervised this work.

AUTHORSHIP CONTRIBUTIONS

Writing Group: L.A.C., R.S.F., T.M.F., M. Graff, H.M.H., J.N.H., A.E.J., T.K., Z.K., C.M.L., R.J.F.L., Y.L., K.E.N., V.T., K.L.Y.

Data preparation group: T.A., I.B.B., T.E., S.F., M. Graff, H.M.H., A.E.J., T.K., D.J.L., K.S.L., A.E.L., R.J.F.L., Y.L., E. Marouli, N.G.D.M., C.M.-G., P.M., M.C.Y.N., M.A.R., S.S., C.S., K. Stirrups, V.T., S.V., S.M.W., T.W.W., K.L.Y., X.Z.

WHR meta-analyses: P.L.A., H.M.H., A.E.J., T.K., M. Graff, C.M.L., R.J.F.L., K.E.N., V.T., K.L.Y.

Pleiotropy working group: G.A., M. Boehnke, J.P.C., P.D., F.D., J.C.F., H.M.H., H.K., H.M.H., A.E.J., C.M.L., D.J.L., R.J.F.L., A. Mahajan, E. Marouli, G.M., M.I.M., P.B.M., G.M.P., J.R.B.P., K.S.R., X.S., S.W., J.W., C.J.W.

Phenome-wide association studies: L. Bastarache, J.C.D., A.G., A. Mahajan, M.I.M.

Gene-set enrichment analyses: S.B., R.S.F., J.N.H., Z.K., D.L., T.H.P., T.F.V.

eQTL analyses: C.K.R., Y.L., K.L.M.

Monogenic and syndromic gene enrichment analyses: H.M.H., A.K.M.

Fly Obesity Screen: A. Lempradl, J.A. Pospisilik.

Overseeing of contributing studies and consortia: (1958 Birth Cohort) P.D.; (Airwave) P.E.; (AMC PAS) G.K.H.; (Amish) J.R.O.; (ARIC) E.B.; (ARIC, Add Health) K.E.N.; (BRAVE) E.D.A., R.C.; (BRIGHT) P.B.M.; (CARDIA) M.F., P.J.S.; (Cebu Longitudinal Health and Nutrition Survey) K.L.M.; (CHD Exome + Consortium) A.S.B., J.M.M.H., D.F.R., J.D.; (CHES) R.V.; (Clear/eMERGE (Seattle)) G.P.J.; (CROATIA_Korcula) V.V., O. Polasek, I.R.; (deCODE) K. Stefansson, U.T.; (DHS) D.W.B.; (DIACORE) C.A.B.; (DPS) J.T., J. Lindström, M.U.; (DRSEXTRA) T.A.L., R.R.; (EFSOCH) A.T.H., T.M.F.; (EGCUT) T.E.; (eMERGE (Seattle)) E.B.L.; (EPIC-Potsdam) M.B.S., H.B.; (EpiHealth) E.I., P.W.F.; (EXTEND) A.T.H., T.M.F.; (Family Heart Study) I.B.B.; (Fenland, EPIC) R.A.S.; (Fenland, EPIC, InterAct) N.J.W., C.L.; (FINRISK) S. Männistö; (FINRISK 2007 (T2D)) P.J., V. Salomaa; (Framingham Heart Study) L.A.C.; (FUSION) M. Boehnke, F.S.C.; (FVG) P.G.; (Generation Scotland) C.H., B.H.S.; (Genetic Epidemiology Network of Arteriopathy (GENOA)) S.L.R.K.; (GRAPHIC) N.J.S.; (GSK-STABILITY) D.M.W., L.W., H.D.W.; (Health) A. Linneberg; (HELIC MANOLIS) E.Z., G.D.; (HELIC Pomak) E.Z., G.D.; (HUNT-MI) K.H., C.J.W.; (Inter99) T.H., T.J.; (IRASFS) L.E.W., E.K.S.; (Jackson Heart Study (JHS)) J.G.W.; (KORA S4) K. Strauch, I.M.H.; (Leipzig-Adults) M. Blüher, P. Kovacs; (LOLIPOP-Exome) J.C.C., J.S.K.; (LOLIPOP-OmniEE) J.C.C., J.S.K.; (MESA) J.I.R., X.G.; (METSIM) J.K., M.L.; (MONICA-Brianza) G.C.; (Montreal Heart Institute Biobank (MHIBB)) M.P.D., G.L., S.d.D., J.C.T.; (MORGAM Central Laboratory) M.P.; (MORGAM Data Centre) K.K.; (OBB) F. Karpe; (PCOS) A.P.M., C.M.L.; (PIVUS) C.M.L., L.L.; (PRIME - Belfast) F. Kee; (PRIME - Lille) P.A.; (PRIME - Strasbourg) M.M.; (PRIME - Toulouse) J.F.; (PROMIS) D.S.; (QC) M.A.R.; (RISC) B.B., E.F., M.W.; (Rotterdam Study I) A.G.U., M.A.I.; (SEARCH) A.M.D.; (SHIP/SHIP-Trend) M.D.; (SIBS) D.F.E.; (SOLID TIMI-52) D.M.W.; (SORBS) A.P.M., M.S., A. Tönjes; (The Mount Sinai BioMe Biobank) E.P.B., R.J.F.L.; (The NEO Study) D.O.M.K.; (The NHAPC study, The GBTDS study) X.L.; (The Western Australian Pregnancy Cohort (Raine) Study) C.E.P., S. Macgregor; (TwinsUK) T.D.S.; (ULSAM) A.P.M.; (Vejle Biobank) I.B., C.C., O. Pedersen; (WGHS) D.I.C., P.M.R.; (Women's Health Initiative) P.L.A.; (WTCCC-UKT2D) M.I.M., K.R.O.; (YFS) T.L., O.T.R.

Genotyping of contributing studies and consortia: (1958 Birth Cohort) K.E.S.; (Airwave) E.E., M.S.L.; (AMC PAS) S.S.; (Amish) L.M.Y.A., J.A. Perry; (ARIC) E.W.D., M.L.G.; (BBMRI-NL) S.H.V., L. Broer, C.M.v.D., P.I.W.d.B.; (BRAVE) E.D.A.; (Cambridge Cancer Studies) J.G.D.; (CARDIA) M.F.; (CHD Exome + Consortium) A.S.B., J.M.M.H., D.F.R., J.D., R.Y.; (Clear/eMERGE (Seattle)) G.P.J.; (CROATIA_Korcula) V.V.; (DIACORE) C.A.B., M. Gorski; (DPS) A.U.J., J. Lindström; (DRSEXTRA) P. Komulainen; (EGCUT) T.E.; (EPIC-Potsdam) M.B.S., K.M.; (EpiHealth) E.I., P.W.F.; (Family Heart Study) K.D.T.; (Fenland, EPIC) R.A.S.; (Fenland, EPIC, InterAct) N.J.W., C.L.; (FUSION) N.N.; (FVG) I.G., A. Morgan; (Generation Scotland) C.H.; (Genetic Epidemiology Network of Arteriopathy (GENOA)) S.L.R.K., J.A.S.; (GRAPHIC) N.J.S.; (GSK-STABILITY) D.M.W.; (Health) J.B.J.; (HELIC MANOLIS) L. Southam; (HELIC Pomak) L. Southam; (Inter99) T.H., N.G.; (KORA) M.M.N.; (KORA S4) K. Strauch, H.G.; (Leipzig-Adults) A. Mahajan; (LOLIPOP-Exome) J.C.C., J.S.K.; (LOLIPOP-OmniEE) J.C.C., J.S.K.; (MESA) J.I.R., Y.D.I.C., K.D.T.; (METSIM) J.K., M.L.; (Montreal Heart Institute Biobank (MHIBB)) M.P.D.; (OBB) F. Karpe; (PCOS) A.P.M.; (PIVUS) C.M.L.; (Rotterdam Study I) A.G.U., C.M.G., F.R.; (SDC) J.M.J., H.V.; (SEARCH) A.M.D.; (SOLID TIMI-52) D.M.W.; (SORBS) A.P.M.; (The Mount Sinai BioMe Biobank) E.P.B., R.J.F.L., Y.L., C.S.; (The NEO Study) R.L.G.; (The NHAPC study, The GBTDS study) X.L., H.L., Y.H.; (The Western Australian Pregnancy Cohort (Raine) Study) C.E.P., S. Macgregor; (TUDR) Z.A.; (TwinsUK) A.P.M.; (ULSAM) A.P.M.; (WGHS) D.I.C., A.Y.C.; (Women's Health Initiative) A.P.R.; (WTCCC-UKT2D) M.I.M.; (YFS) T.L., L.P.L.

Phenotyping of contributing studies and consortia: (Airwave) E.E.; (AMC PAS) S.S.; (Amish) L.M.Y.A.; (ARIC) E.W.D.; (ARIC, Add Health) K.E.N.; (BBMRI-NL) S.H.V.; (BRAVE) E.D.A.; (BRIGHT) M.J.C.; (CARL) A. Robino, G.G.; (Cebu Longitudinal Health and Nutrition Survey) N.R.L.; (CHES) R.V., M.T.; (Clear/eMERGE (Seattle)) G.P.J., A.A.B.; (CROATIA_Korcula) O. Polasek, I.R.; (DIACORE) C.A.B., B.K.K.; (DPS) A.U.J., J. Lindström; (EFSOCH) A.T.H.; (EGCUT) E. Mihailov; (EPIC-Potsdam) H.B.; (EpiHealth) E.I.; (EXTEND) A.T.H.; (Family Heart Study) M.F.F.; (Fenland, EPIC, InterAct) N.J.W.; (FIN-D2D 2007) L.M., M.V.; (FINRISK) S. Männistö; (FINRISK 2007 (T2D)) P.J., H.M.S.; (Framingham Heart Study) C.S.F.; (Generation Scotland) C.H., B.H.S.; (Genetic Epidemiology Network of Arteriopathy (GENOA)) S.L.R.K., J.A.S.; (GRAPHIC) N.J.S.; (GSK-STABILITY) L.W., H.D.W.; (Health) A. Linneberg, B.H.T.; (HELIC MANOLIS) L. Southam, A.E.F., E.T.; (HELIC Pomak) L. Southam, A.E.F., M.K.; (HUNT-MI) K.H., O.L.H.; (Inter99) T.J., N.G.; (IRASFS) L.E.W., B.K.; (KORA) M.M.N.; (BBMRI-NL) K.M.A.S.; (Leipzig-Adults) M. Blüher, P. Kovacs; (LOLIPOP-Exome) J.C.C., J.S.K.; (LOLIPOP-OmniEE) J.C.C., J.S.K.; (MESA) M.A.; (Montreal Heart Institute Biobank (MHIBB)) G.L., K.S.L., V.T.; (MORGAM Data Centre) K.K.; (OBB) F. Karpe, M.N.; (PCOS) C.M.L.; (PIVUS) L.L.;

PROTEIN-CODING VARIANTS IMPLICATE NOVEL GENES RELATED TO LIPID HOMEOSTASIS CONTRIBUTING TO BODY FAT DISTRIBUTION

A full list of authors and affiliations appears at the end of the article.

Abstract

Body fat distribution is a risk factor for adverse cardiovascular health consequences. We analyzed the association of body fat distribution, assessed by waist-to-hip ratio adjusted for body mass index, with 228,985 predicted coding and splice site variants available on exome arrays in up to 344,369 individuals from five major ancestries (discovery) and 132,177 European-ancestry individuals (validation). We identified 15 common (minor allele frequency, MAF \geq 5%) and 9 low frequency or rare (MAF $<$ 5%) coding novel variants. Pathway/gene set enrichment analyses identified lipid particle, adiponectin, abnormal white adipose tissue physiology, and bone development and morphology as important contributors to fat distribution, while cross-trait associations highlight cardiometabolic traits. In functional follow-up analyses, specifically in *Drosophila* RNAi-knockdowns, we observed a significant increase in the total body triglyceride

(PRIME - Belfast) F. Kee; (PRIME - Lille) P.A.; (PRIME - Strasbourg) M.M.; (PRIME - Toulouse) J.F.; (RISC) B.B., E.F.; (Rotterdam Study I) M.A.I., C.M.G., F.R., M.C.Z.; (SHIP/SHIP-Trend) N.F.; (SORBS) M.S., A. Tönjes; (The Mount Sinai BioMe Biobank) E.P.B., Y.L., C.S.; (The NEO Study) R.d.M.; (The NHAPC study, The GBTDS study) X.L., H.L., L. Sun, F.W.; (The Western Australian Pregnancy Cohort (Raine) Study) C.E.P.; (TUDR) Y.J.H., W.J.L.; (TwinsUK) T.D.S., K.S.S.; (ULSAM) V.G.; (WGHS) D.I.C., P.M.R.; (Women's Health Initiative) A.P.R.; (WTCCC-UKT2D) M.I.M., K.R.O.; (YFS) T.L., O.T.R.

Data analysis of contributing studies and consortia: (1958 Birth Cohort) K.E.S., I.N.; (Airwave) E.E., M.S.L.; (AMC PAS) S.S.; (Amish) J.R.O., L.M.Y.A., J.A. Perry; (ARIC, Add Health) K.E.N., K.L.Y., M. Graff; (BBMRI-NL) L. Broer; (BRAVE) R.C., D.S.A.; (BRIGHT) H.R.W.; (Cambridge Cancer Studies) J.G.D., A.E., D.J.T.; (CARDIA) C.E.L., M.F., L.-A.L.; (CARL) A. Robino, D.V.; (Cebu Longitudinal Health and Nutrition Survey) Y.W.; (CHD Exome + Consortium) A.S.B., J.M.M.H., D.F.R., R.Y., P.S.; (CHES) Y.J.; (CROATIA_Korcula) V.V.; (deCODE) V. Steinthorsdottir, G.T.; (DHS) A.J.C., P.M., M.C.Y.N.; (DIACORE) C.A.B., M. Gorski; (EFSOCH) H.Y.; (EGCUT) T.E., R.M.; (eMERGE (Seattle)) D.S.C.; (ENDO) T.K.; (EPIC) J.H.Z.; (EPIC-Potsdam) K.M.; (EpiHealth) S.G.; (EXTEND) H.Y.; (Family Heart Study) M.F.F.; (Fenland) J.Luan; (Fenland, EPIC) R.A.S.; (Fenland, InterAct) S.M.W.; (FIN-D2D 2007) M. V., L.M.; (Finnisk Extremes and QC) S.V.; (Framingham Heart Study) C.T.L., N.L.H.C.; (FVG) I.G.; (Generation Scotland) C.H., J.M.; (Genetic Epidemiology Network of Arteriopathy (GENOA)) L.F.B.; (GIANT-Analyst) A.E.J.; (GRAPHIC) N.J.S., N.G.D.M., C.P.N.; (GSK-STABILITY) D.M.W., A.J.S.; (Health) J.B.J.; (HELIC MANOLIS) L. Southam; (HELIC Pomak) L. Southam; (HUNT-MI) W. Zhou; (Inter99) N.G.; (IRASFS) B.K.; (Jackson Heart Study (JHS)) L.A.L., J. Li; (KORA S4) T.W.W.; (BBMRI-NL) K.M.A.S.; (Leipzig-Adults) A. Mahajan; (LOLIPOP-Exome) J.C.C., J.S.K., W. Zhang; (LOLIPOP-OmnIE) J.C.C., J.S.K., Weihua Zhang; (MESA) J.I.R., X.G., J.Y.; (METSIM) X.S.; (Montreal Heart Institute Biobank (MHIBB)) J.C.T., G.L., K.S.L., V.T.; (OBB) A. Mahajan; (PCOS) A.P.M., T.K.; (PIVUS) N.R.R.; (PROMIS) A. Rasheed, W. Zhao; (QC GoT2D/T2D-GENES (FUSION, METSIM, etc)) A.E.L.; (RISC) H.Y.; (Rotterdam Study I) C.M.G., F.R.; (SHIP/SHIP-Trend) A. Teumer; (SOLID TIMI-52) D.M.W., A.J.S.; (SORBS) A.P.M.; (The Mount Sinai BioMe Biobank) Y.L., C.S.; (The NEO Study) R.L.G.; (The NHAPC study, The GBTDS study) X.L., H.L., Y.H., H.Z.; (The Western Australian Pregnancy Cohort (Raine) Study) C.A.W.; (UK Biobank) A.R.W.; (ULSAM) A.P.M., A. Mahajan; (WGHS) D.I.C., A.Y.C.; (Women's Health Initiative) P.L.A., J.H.; (WTCCC-UKT2D) W.G.; (YFS) L.P.L.

COMPETING INTERESTS

The authors declare the following competing interests: ASB holds interest in AstraZeneca, Biogen, Bioverativ, Merck, Novartis and Pfizer. ASC and CSF are current employees of Merck. Authors affiliated with deCODE (VSt, GT, UT and KS) are employed by deCODE Genetics/Amgen, Inc. HDW has the following financial and non-financial competing interests to declare: Research Grants: Sanofi Aventis; Eli Lilly; NIH; Omthera Pharmaceuticals, Pfizer, Eisai Inc. AstraZeneca; DalCor and Services; Lecture fees: Sanofi Aventis; Advisory Boards: Acetelion, Sirtex, CSL Boehringer. JD has received grants from AstraZeneca, Biogen, Merck, Novartis and Pfizer. LMYA and RAS are employee stock holders of GlaxoSmithKline. MPD received honoraria and holds minor equity in Dalcor. VS has participated in a conference trip sponsored by Novo Nordisk.

DATA AVAILABILITY

Summary statistics of all analyses are available at https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files.

levels for two genes (*DNAH10* and *PLXND1*). We implicate novel genes in fat distribution, stressing the importance of interrogating low-frequency and protein-coding variants.

Editorial summary:

A trans-ethnic exome-wide association study for body fat distribution identifies protein-coding variants that are significantly associated with waist-to-hip ratio adjusted for body mass index.

Central body fat distribution, as assessed by waist-to-hip ratio (WHR), is a heritable and a well-established risk factor for adverse metabolic outcomes^{1–6}. Lower values of WHR are associated with lower risk of cardiometabolic diseases like type 2 diabetes (T2D)^{7,8}, or differences in bone structure and gluteal muscle mass⁹. These epidemiological associations are consistent with our previously reported genome-wide association study (GWAS) results of 49 loci associated with WHR (after adjusting for body mass index, WHRadjBMI)¹⁰. Notably, genetic predisposition to higher WHRadjBMI is associated with increased risk of T2D and coronary heart disease (CHD), which appears to be causal⁹.

Recently, large-scale studies have identified ~125 common loci for multiple measures of central obesity, primarily non-coding variants of relatively modest effect^{10–16}. Large scale interrogation of coding and splice site variants, including both common (minor allele frequency [MAF] ≥ 5%) and low frequency or rare (LF/RV, MAF < 5%), may lead to additional insights into the etiology of central obesity. Herein, we identify and characterize such variants associated with WHRadjBMI using ExomeChip array genotypes.

RESULTS

Protein-coding and splice site variation associations

We conducted a 2-stage fixed-effects meta-analysis testing additive and recessive models to detect protein-coding genetic variants that influence WHRadjBMI (Online Methods, Figure 1). Stage 1 included up to 228,985 variants (218,195 LF/RV) in up to 344,369 individuals from 74 studies of European, South and East Asian, African, and Hispanic/Latino descent individuals (Supplementary Data 1–3). Stage 2 assessed 70 suggestive ($P < 2 \times 10^{-6}$) Stage 1 variants in two cohorts, UK Biobank (UKBB) and deCODE for a total Stage 1+2 sample size of 476,546 (88% European). Of the 70 variants considered, two common and five LF/RV were not available in Stage 2 (Tables 1–2, Supplementary Data 4–6). Variants are considered novel and statistically significant if they were greater than one megabase (Mb) from a previously-identified WHRadjBMI SNP^{10–16} and achieve array-wide significance ($P < 2 \times 10^{-7}$, Stage 1+2).

In our primary meta-analysis, including all Stage 1+2 samples, we identified 48 coding variants (16 novel) across 43 genes, 47 assuming an additive model, and one under a recessive model (Table 1, Supplementary Figures 1–4). Due to possible heterogeneity, we also performed European-only meta-analysis. Here, four additional coding variants were significant (three novel) assuming an additive model (Table 1, Supplementary Figures 5–8). Of these 52 significant variants, eleven were LF/RV and displayed larger effect estimates than many previously reported common variants¹⁰, including seven novel variants in

RAPGEF3, *FGFR2*, *R3HDML*, *HIST1H1T*, *PCNXL3*, *ACVR1C*, and *DARS2*. Variants with MAF $\geq 1\%$ had effect sizes approximately three times greater than those of common variants (MAF $\geq 5\%$). Despite large sample size, we cannot rule out the possibility that additional LF/RV with smaller effects exist (See estimated 80% power in Figure 2). However, in the absence of common variants with similarly large effects, our results point to the importance of investigating LF/RV.

Given established sex differences in the genetic underpinnings of WHRadjBMI^{10,11}, we also performed sex-stratified analyses. We detected four additional novel variants that exhibit significant sex-specific effects ($P_{\text{sexhet}} < 7.14 \times 10^{-4}$, Online Methods) in *UGGT2* and *MMP14* for men; and *DSTYK* and *ANGPTL4* for women (Table 2, Supplementary Figures 9–15); including LF/RV in *UGGT2* and *ANGPTL4* (MAF_{men} = 0.6% and MAF_{women} = 1.9%, respectively). Additionally, 14 variants from the sex-combined meta-analyses displayed significantly stronger effects in women, including the novel, LF/RV in *ACVR1C* (rs55920843, MAF=1.1%). Overall, 19 of the 56 variants (32%) identified across all meta-analyses (48 from all ancestry, 4 from European-only and 4 from sex-stratified analyses) showed significant sex-specific effects on WHRadjBMI: 16 variants with significantly stronger effects in women, and three in men (Figure 1).

In summary, we identified 56 array-wide significant coding variants ($P < 2.0 \times 10^{-7}$); 43 common (14 novel) and 13 LF/RV (9 novel). For the 55 significant variants from the additive model, we examined potential collider bias^{17,18} (Online Methods, Supplementary Table 1, Supplementary Note). Overall, 51 of 55 variants were robust to collider bias^{17,18}. Of these, 25 variants were nominally associated with BMI ($P_{\text{BMI}} < 0.05$), yet effect sizes changed little after correction for potential biases (15% change in effect estimate on average). For four of the 55 SNPs (rs141845046, rs1034405, rs3617, rs9469913), attenuation following correction was noted ($P_{\text{corrected}} > 9 \times 10^{-4}$, 0.05/55), including one novel variant, rs1034405 in *C3orf18*, demonstrating a possible overestimation of these effects in the current analysis.

Using Stage 1 results, we then aggregated LF/RV across genes and tested their joint effect with SKAT and burden tests¹⁹ (Supplementary Table 2, Online Methods). None of the five genes that reached array-wide significance ($P < 2.5 \times 10^{-6}$, 0.05/16,222 genes tested: *RAPGEF3*, *ACVR1C*, *ANGPTL4*, *DNAI1*, and *NOP2*) remained significant after conditioning on the most significant single variant.

Conditional analyses

We next implemented conditional analyses to determine (1) the total number of independent signals identified, and (2) whether the 33 variants near known GWAS signals (± 1 Mb) represent independent novel associations. We used approximate joint conditional analyses to test for independence in Stage 1 (Online Methods; Supplementary Table 3)¹⁹. Only the *RSPO3-KIAA0408* locus contains two independent variants 291 Kb apart, rs1892172 in *RSPO3* (MAF = 46.1%, $P_{\text{conditional}} = 4.37 \times 10^{-23}$ in the combined sexes, and $P_{\text{conditional}} = 2.4 \times 10^{-20}$ in women) and rs139745911 in *KIAA0408* (MAF = 0.9%, $P_{\text{conditional}} = 3.68 \times 10^{-11}$ in combined sexes, and $P_{\text{conditional}} = 1.46 \times 10^{-11}$ in women; Figure 3a). For the 33 variants within one Mb of previously identified WHRadjBMI SNPs, sex-combined

conditional analyses identified one coding variant representing a novel independent signal in a known locus [*RREB1*; Stage 1 meta-analysis, rs1334576, EAF=44%, $P_{\text{conditional}} = 3.06 \times 10^{-7}$, (Supplementary Data 7, Figure 3b); UKBB analysis, rs1334576, *RREB1*, $P_{\text{conditional}} = 1.24 \times 10^{-8}$, (Supplementary Table 4).

In summary, we identified 56 WHRadjBMI-associated coding variants in 41 independent association signals, 24 of which are new or independent of known GWAS-identified tag SNPs (either > 1 MB +/- or array-wide significant following conditional analyses) (Figure 1). Thus, we identified 15 common and 9 LF/RV novel and independent variants following conditional analyses.

Gene set and pathway enrichment analysis

To determine if significant coding variants highlight novel or previously identified biological pathways, we applied two complementary methods, EC-DEPICT (ExomeChip Data-driven Expression Prioritized Integration for Complex Traits)^{20,21} and PASCAL²² (Online Methods). For PASCAL all variants were used, for EC-DEPICT we examined only 361 variants with suggestive significance ($P < 5 \times 10^{-4}$)^{10,23} from the all ancestries combined sexes analysis (which after clumping and filtering became 101 lead variants in 101 genes). We separately analyzed variants that exhibited significant sex-specific effects ($P_{\text{sexhet}} < 5 \times 10^{-4}$).

The sex-combined analyses identified 49 significantly enriched gene sets (FDR < 0.05) that grouped into 25 meta-gene sets (Supplementary Note, Supplementary Data 8–9). We noted a cluster of meta-gene sets with direct relevance to metabolic aspects of obesity (“enhanced lipolysis,” “abnormal glucose homeostasis,” “increased circulating insulin level,” and “decreased susceptibility to diet-induced obesity”); we observed two significant adiponectin-related gene sets within these meta-gene sets. While these pathway groups had previously been identified in the GWAS DEPICT analysis (Figure 4), many of the individual gene sets within these meta-gene sets were not significant in the previous GWAS analysis, such as “insulin resistance,” “abnormal white adipose tissue physiology,” and “abnormal fat cell morphology” (Supplementary Data 8, Figure 4, Supplementary Figure 16a), but represent similar biological underpinnings implied by the shared meta-gene sets. Despite their overlap with the GWAS results, these analyses highlight novel genes that fall outside known GWAS loci and with strong contributions to the significantly enriched gene sets related to adipocyte and insulin biology (e.g. *MLXIPL*, *ACVR1C*, and *ITIH5*) (Figure 4).

Also, we conducted pathway analyses after excluding variants from previous WHRadjBMI analyses¹⁰ (Supplemental Note). Seventy-five loci/genes were included in the EC-DEPICT analysis, and we identified 26 significantly enriched gene sets (13 meta-gene sets). Here, all but one gene set, “lipid particle size”, were related to skeletal biology, likely reflecting an effect on the pelvic skeleton (hip circumference), shared signaling pathways between bone and fat (such as TGF-beta) and shared developmental origin²⁴ (Supplementary Data 9, Supplementary Figure 16b). These previously identified GWAS DEPICT significant findings provide a fully independent replication of their biological relevance for WHRadjBMI.

We used PASCAL (Online Methods) to further distinguish between enrichment based on *coding-only* variant associations (this study) and *regulatory-only* variant associations (up to 20 kb upstream of the gene from a previous GIANT study¹⁰), finding 116 significantly enriched coding pathways (FDR < 0.05; Supplementary Data 10). We also compared the coding pathways to those identified in the total previous GWAS effort (using both *coding and regulatory* variants) identifying a total of 158 gene sets. Forty-two gene sets were enriched in both analyses, and we found high concordance in the $-\log_{10}$ (p -values) between ExomeChip and GWAS gene set enrichment [Pearson's r (coding vs regulatory only) = 0.38, $P < 10^{-300}$; Pearson's r (coding vs coding+regulatory) = 0.51, $P < 10^{-300}$]. Nonetheless, some gene sets were enriched *specifically* for variants in coding regions (e.g., decreased susceptibility to diet-induced obesity, abnormal skeletal morphology) or unique to variants in regulatory regions (e.g. transcriptional regulation of white adipocytes) (Supplementary Figure 17).

The EC-DEPICT and PASCAL results showed a moderate but strongly significant correlation (for EC-DEPICT and the PASCAL max statistic, $r = .28$, $P = 9.8 \times 10^{-253}$; for EC-DEPICT and the PASCAL sum statistic, $r = 0.287$, $P = 5.42 \times 10^{-272}$). Common gene sets strongly implicate a role for skeletal biology, glucose homeostasis/insulin signaling, and adipocyte biology (Supplementary Figure 18).

Cross-trait associations

To assess the clinical relevance of our identified variants with cardiometabolic, anthropometric, and reproductive traits, we conducted association lookups from existing ExomeChip studies of 15 traits (Supplementary Data 11, Supplementary Figure 19).^{21,25–29} Variants in *STAB1* and *PLCB3* displayed the greatest number of significant associations with seven different traits ($P < 9.8 \times 10^{-4}$, 0.05/51 variants tested). Also, these two genes cluster together with *RSPO3*, *DNAH10*, *MNS1*, *COBLL1*, *CCDC92*, and *ITIH3*. The WHR-increasing alleles in this cluster exhibit a previously described pattern of increased cardiometabolic risk (e.g. increased fasting insulin, two-hour glucose [TwoHGlu], and triglycerides; and decreased high-density lipoprotein cholesterol [HDL]), but also decreased BMI.^{30–36} The impact of central obesity may be causal, as a 1 SD increase in genetic risk of central adiposity was previously associated with higher total cholesterol, triglycerides, fasting insulin and TwoHGlu, and lower HDL.⁹

We conducted a search in the NHGRI-EBI GWAS Catalog^{37,38} to determine if our variants are in high LD ($R^2 > 0.7$) with variants associated with traits or diseases not covered by our cross trait lookups (Supplementary Data 12). We identified several cardiometabolic traits (adiponectin, coronary heart disease, *etc.*), diet/behavioral traits potentially related to obesity (carbohydrate, fat intake, *etc.*), behavioral and neurological traits (schizophrenia, bipolar disorder, *etc.*), and inflammatory or autoimmune diseases (Crohn's Disease, multiple sclerosis, *etc.*).

Given the established correlation between total body fat percentage and WHR of up to 0.483^{39–41}, we examined the association of our top exome variants with both total body fat percentage (BF%) and truncal fat percentage (TF%) available in a sub-sample of UKBB (N = 118,160) (Supplementary Tables 5–6). Seven of the common novel variants were

significantly associated ($P < 0.001$, 0.05/48 variants examined) with both BF% and TF% in the sexes-combined analysis (*COBLL1*, *UHRF1BP1*, *WSCD2*, *CCDC92*, *IFI30*, *MPV17L2*, *IZUMO1*) and two with TF% in women only (*EFCAB12*, *GDF5*). Only rs7607980 in *COBLL1* is near a known BF% GWAS locus (rs6738627; $R^2 = 0.1989$, distance = 6,751 bp, with our tag SNP)⁴². Of the nine SNPs associated with at least one of these two traits, all variants displayed much greater magnitude of effect on TF% compared to BF% (Supplementary Figure 20).

Previous studies have demonstrated the importance of examining common and LF/RV within genes with mutations known to cause monogenic diseases.^{43,44} Thus, we assessed enrichment of WHRadjBMI variants within monogenic lipodystrophy and/or insulin resistance genes.^{43,44} (Supplementary Data 13). No significant enrichment was observed, possibly due in part to the small number of implicated genes and the relatively small number of variants in monogenic disease-causing genes (Supplementary Figure 21).

Genetic architecture of WHRadjBMI coding variants

We used summary statistics from our Stage 1 primary meta-analysis results to estimate the phenotypic variance explained by subsets of variants across various significance thresholds ($P < 2 \times 10^{-7}$ to 0.2) and conservatively using only independent SNPs (Supplementary Table 7, Online Methods, and Supplementary Figure 22). For only independent coding variants that reached suggestive significance in Stage 1 ($P < 2 \times 10^{-6}$), 33 SNPs explain 0.38% of the variation. The 1,786 independent SNPs with a liberal threshold of $P < 0.02$ explain 13 times more variation (5.12%), however, these large effect estimates may be subject to winner's curse. When considering all coding variants on the ExomeChip in combined sexes, 46 SNPs with a $P < 2 \times 10^{-6}$ and 5,917 SNPs with a $P < 0.02$ explain 0.51% and 13.75% of the variance in WHRadjBMI, respectively. As expected given the design of the ExomeChip, the majority of the variance explained is attributable to rare and low frequency coding variants. However, for LF/RVs, those that passed significance in Stage 1 explain only 0.10% of the variance in WHRadjBMI. We also estimated variance explained for the same SNPs in women and men separately and observed a greater variance explained in women compared to men ($P_{\text{RsqDiff}} < 0.002 = 0.05/21$, Bonferroni-corrected threshold) at each significance threshold considered (differences ranged from 0.24% to 0.91%).

We conducted penetrance analysis using the UKBB (both sexes combined, and men- and women-only) to determine if there is a significant accumulation of the minor allele in either the centrally obese or non-obese groups (Online Methods). Three rare variants (MAF $\approx 1\%$) with larger effect sizes (effect size > 0.90) were included in the penetrance analysis using World Health Organization cut-offs for central obesity. Of these, one SNP (rs55920843-*ACVR1C*; $P_{\text{sex-combined}} = 9.25 \times 10^{-5}$; $P_{\text{women}} = 4.85 \times 10^{-5}$) showed a statistically significant difference in the number of carriers and non-carriers of the minor allele in the combined and female-only analysis (sex-combined obese carriers = 2.2%; non-obese carriers = 2.6%; women obese carriers = 2.1%; non-obese women carriers = 2.6%, Supplementary Table 8, Supplementary Figure 23).

Drosophila Knockdown—Considering the genetic evidence of adipose and insulin biology in determining body fat distribution¹⁰, and the lipid signature of the variants described herein, we examined whole-body triglyceride levels in adult *Drosophila*, a model organism in which the fat body is an organ functionally analogous to mammalian liver and adipose tissue as triglycerides are the major source of fat storage⁴⁵. Of the 51 genes harboring our 56 significantly associated variants, we identified 27 *Drosophila* orthologues for functional follow-up analyses. We selected genes with large changes in triglyceride levels (> 20% increase or > 40% decrease, as chance alone is unlikely to cause changes of this magnitude) from an existing large-scale screen with 2 replicates per knockdown strain.⁴⁵ Two orthologues, for *PLXND1* and *DNAH10*, met these criteria and were subjected to additional knockdown experiments with 5 replicates using tissue-specific drivers (fat body [cg-Gal4] and neuronal [elav-Gal4] specific RNAi-knockdowns) (Supplementary Table 9). A significant ($P < 0.025$, 0.05/2 orthologues) increase in the total body triglyceride levels was observed in *DNAH10* orthologue knockdown strains for both the fat body and neuronal drivers. Only the neuronal driver knockdown for *PLXND1* produced a significant change in triglyceride storage. *DNAH10* and *PLXND1* both lie within previous GWAS identified regions. Adjacent genes have been highlighted as likely candidates for the *DNAH10* association region, including *CCDC92* and *ZNF664* based on expression quantitative trait locus (eQTL) evidence. Of note, rs11057353 in *DNAH10* showed suggestive significance after conditioning on the known GWAS variants in nearby *CCDC92* (sex-combined $P_{\text{conditional}} = 7.56 \times 10^{-7}$; women-only rs11057353 $P_{\text{conditional}} = 5.86 \times 10^{-7}$, Supplementary Table 4) thus providing some evidence of multiple causal variants/genes underlying this signal. Further analyses are needed to determine whether the implicated coding variants from the current analysis are the putatively functional variants.

eQTL Lookups

We examined the *cis*-association of variants with expression level of nearby genes in subcutaneous and visceral omental adipose, skeletal muscle, and pancreas tissue from the Genotype-Tissue Expression (GTEx)⁴⁶ project, and assessed whether exome and eQTL associations implicated the same signal (Online Methods, Supplementary Data 14–15). The lead exome variant was associated with expression level of the gene itself for *DAGLB*, *MLXIPL*, *CCDC92*, *MAPKBPI*, *LRRC36* and *UQCC1*. However, for *MLXIPL*, *MAPKBPI*, and *LRRC36*, the lead variant is also associated with expression of additional nearby genes. At three additional loci, the lead exome variant is only associated with expression level of nearby genes (*HEMK1* at *C3orf18*; *NT5DC2*, *SMIM4* and *TMEM110* at *STAB1/ITIH3*; and *C6orf106* at *UHRF1BPI*). Thus, although detected with a missense variant, these results are also consistent with a regulatory mechanism of effect, and the association signal may well be due to linkage disequilibrium (LD) with nearby regulatory variants.

Some of the coding genes implicated by eQTL analyses are known to be involved in adipocyte differentiation or insulin sensitivity: e.g. for *MLXIPL*, the encoded carbohydrate responsive element binding protein is a transcription factor, regulating glucose-mediated induction of *de novo* lipogenesis in adipose tissue, and expression of its *beta*-isoform in adipose tissue is positively correlated with adipose insulin sensitivity^{47,48}. For *CCDC92*, the

reduced adipocyte lipid accumulation upon knockdown confirmed the involvement of its encoded protein in adipose differentiation⁴⁹.

Biological Curation

To investigate the possible functional role of the identified variants, we conducted thorough searches of the literature and publicly available bioinformatics databases (Supplementary Data 16–17, Box 1, Online Methods). Many of our novel LF/RV are in genes that are intolerant of nonsynonymous mutations (e.g. *ACVR1C*, *DARS2*, *FGFR2*; ExAC Constraint Scores >0.5). Other coding variants lie within genes that are involved in glucose homeostasis (e.g. *ACVR1C*, *UGGT2*, *ANGPTL4*), angiogenesis (*RASIP1*), adipogenesis (*RAPGEF3*), and lipid biology (*ANGPTL4*, *DAGLB*).

DISCUSSION

Our analysis of coding variants from ExomeChip data in up to 476,546 individuals identified a total of 56 array-wide significant WHRadjBMI associated variants in 41 independent association signals, including 24 newly identified (23 novel and one independent of known GWAS signals). Nine of these variants were LF/RV, indicating an important role for such variants in the polygenic architecture of fat distribution. While, due to their rarity, these coding variants explain a small proportion of the trait variance at a population level, they may be more functionally tractable than non-coding variants and have a critical impact at the individual level. For instance, the association between a LF/RV (rs11209026; R381Q; MAF < 5% in ExAC) located in the *IL23R* gene and multiple inflammatory diseases^{50–53} led to development of new therapies targeting *IL23* and *IL12* in the same pathway.^{54–56} Thus, we are encouraged that our LF/RV displayed large effect sizes; all but one of the nine novel LF/RV display larger effects than the 49 SNPs reported in Shungin *et al.* 2015¹⁰, and some of these effects were up to 7-fold larger than those previously reported for GWAS. This finding mirrors results for other cardiometabolic traits⁵⁷, and suggests variants of possible clinical significance with even larger effect and rarer variants will likely be detected with greater sample sizes.

We continue to observe sexual dimorphism in the genetic architecture of WHRadjBMI¹¹. We identified 19 coding variants with significant sex differences, of which 16 (84%) display larger effects in women compared to men. Of the variants outside of GWAS loci, we reported three (two LF/RV) that show a significantly stronger effect in women and two (one LF/RV) that show a stronger effect in men. Genetic variants continue to explain a higher proportion of the phenotypic variation in body fat distribution in women compared to men.^{10,11} Of the novel female (*DSTYK* and *ANGPTL4*) and male (*UGGT2* and *MMP14*) specific signals, only *ANGPTL4* implicated fat distribution related biology associated with both lipid biology and cardiovascular traits (Box 1). Sexual dimorphism in fat distribution is apparent^{58–60} and at sexually dimorphic loci, hormones with different levels in men and women may interact with genomic and epigenomic factors to regulate gene activity, though this remains to be tested. Dissecting the underlying molecular mechanisms of the sexual dimorphism in body fat distribution, and how it is correlated with – and causing – important

comorbidities like cardiometabolic diseases will be crucial for improved understanding of disease pathogenesis.

Overall, we observe fewer significant associations, pathways, and cross-trait associations between WHRadjBMI and coding variants on the ExomeChip than Turcot *et al* for BMI²⁵. One reason for this may be smaller sample size ($N_{\text{WHRadjBMI}} = 476,546$, $N_{\text{BMI}} = 718,639$), and thus, lower statistical power. Power is likely not the only contributing factor, as trait architecture, heritability (possibly overestimated in some phenotypes), and phenotype precision all likely contribute to our study's capacity to identify LF/RV with large effects. Further, it is possible that the comparative lack of significant findings for WHRadjBMI may be a result of higher selective pressure against genetic predisposition to cardiometabolic phenotypes, thus rarer risk variants.⁶¹ The ExomeChip is limited by the variants present on the chip, which was largely dictated by sequencing studies in European-ancestry populations and MAF detection criteria of ~0.012%. It is likely that through increased sample size, use of chips designed to detect variation across a range of continental ancestries, and high quality, deep imputation with large reference samples future studies will detect additional variation from the entire allele frequency spectrum that contributes to fat distribution.

The collected genetic and epidemiologic evidence has demonstrated that increased central adiposity is correlated with risk of T2D and CVD, and that this association is likely causal with potential mediation through blood pressure, triglyceride-rich lipoproteins, glucose, and insulin⁹. This observation yields an immediate follow-up question: Which mechanisms regulate depot-specific fat accumulation and are risks for disease driven by increased visceral and/or decreased subcutaneous adipose tissue mass. Pathway analysis identified several novel pathways and gene sets related to metabolism and adipose regulation, bone growth and development and adiponectin, a hormone which has been linked to “healthy” expansion of adipose tissue and insulin sensitivity.⁶² Similarly, expression/eQTL results support the relevance of adipogenesis, adipocyte biology, and insulin signaling, supporting our previous findings for WHRadjBMI.¹⁰ We also provide evidence suggesting known biological functions and pathways contributing to body fat distribution (e.g., diet-induced obesity, angiogenesis, bone growth/morphology, and lipolysis).

The ultimate aim of genetic investigations of obesity-related traits is to identify dysregulated genomic pathways leading to obesity pathogenesis that may result in a myriad of downstream illnesses. Thus, our findings may enhance the understanding of central obesity and identify new molecular targets to avert its negative health consequences. Significant cross-trait associations are consistent with expected direction of effect for several traits, i.e. the WHR-increasing allele is associated with higher values of triglycerides, DBP, fasting insulin, total cholesterol, LDL and T2D across many significant variants. However, it is worth noting that there are some exceptions. For example, rs9469913-A in *UHRF1BP1* is associated with both increased WHRadjBMI and increased HDL. Also, we identified two variants in *MLXIPL* (rs3812316 and rs35332062), a well-known lipids-associated locus, in which the WHRadjBMI-increasing allele also increases all lipid levels, risk for hypertriglyceridemia, SBP and DBP. However, our findings show a significant and negative association with HbA1C, and nominally significant and negative associations with two-hour glucose, fasting glucose, and Type 2 diabetes, and potential negative associations with

biomarkers for liver disease (e.g. gamma glutamyl transpeptidase). Other notable exceptions include *ITIH3* (negatively associated with BMI, HbA1C, LDL and SBP), *DAGLB* (positively associated with HDL), and *STAB1* (negatively associated with total cholesterol, LDL, and SBP). Therefore, caution in selecting pathways for therapeutic targets is warranted; we must look beyond the effects on central adiposity to the potential cascading effects of related diseases.

A major finding from this study is the importance of lipid metabolism for body fat distribution. In fact, pathway analyses that highlight enhanced lipolysis, cross-trait associations with circulating lipid levels, existing biological evidence from the literature, and knockdown experiments in *Drosophila*, point to novel candidate genes (*ANGPTL4*, *ACVR1C*, *DAGLB*, *MGA*, *RASIP1*, and *IZUMO1*) and new candidates in known regions (*DNAH10*¹⁰ and *MLXIPL*¹⁴) related to lipid biology and their role in fat storage. *ACVR1C*, *MLXIPL*, and *ANGPTL4*, all of which are involved in lipid homeostasis, all are excellent candidate genes for central adiposity. Carriers of inactivating mutations in *ANGPTL4* (*Angiopoietin Like 4*), for example, display low triglycerides and low risk of coronary artery disease⁶³. *ACVR1C* encodes the activin receptor-like kinase 7 protein (ALK7), a receptor for the transcription factor TGF β -1, well known for its central role in general growth and development^{64–68}, and adipocyte development particularly⁶⁸. *ACVR1C* exhibits the highest expression in adipose tissue, but is also highly expressed in the brain^{69–71}. In mice, decreased activity of *ACVR1C* upregulates PPAR γ and C/EBP α pathways and increases lipolysis in adipocytes, thus decreasing weight and diabetes.^{69,72,73} Such activity suggests a role for ALK7 in adipose tissue signaling and a possible therapeutic target. *MLXIPL*, also important for lipid metabolism and postnatal cellular growth, encodes a transcription factor which activates triglyceride synthesis genes in a glucose-dependent manner.^{74,75} The lead exome variant in *MLXIPL* is highly conserved, most likely damaging, and associated with reduced *MLXIPL* expression in adipose tissue. Furthermore, in a recent longitudinal, *in vitro* transcriptome analysis of adipogenesis in human adipose-derived stromal cells, gene expression of *MLXIPL* was up-regulated during the maturation of adipocytes, suggesting a critical role in the regulation of adipocyte size and accumulation.⁷⁶ However, given our cross-trait associations with variants in *MLXIPL* and diabetes-related traits, development of therapeutic targets must be approached cautiously.

Our 24 novel variants for WHRadjBMI highlight the importance of lipid metabolism in the genetic underpinnings of body fat distribution. We continue to demonstrate the critical role of adipocyte biology and insulin resistance for central obesity and offer support for potentially causal genes underlying previously identified fat distribution loci. Notably, our findings offer potential new therapeutic targets for intervention in the risks associated with abdominal fat accumulation and represents a major advance in our understanding of the underlying biology and genetic architecture of central adiposity.

ONLINE METHODS

Studies

Stage 1 included 74 studies (12 case/control, 59 population-based, and five family) comprising 344,369 adults of European (N=288,492), African (N=15,687), South Asian

(N=29,315), East Asian (N=6,800), and Hispanic (N=4,075) descent. Stage 1 meta-analyses were conducted in each ancestry and in all ancestries together, for both sex-combined and sex-specific analyses. Follow-up analyses were performed in 132,177 individuals of European ancestry from deCODE and the UK Biobank, Release 1¹¹² (UKBB) (Supplementary Data 1–3). Informed consent was obtained by the parent study and protocols approved by each study's institutional review boards.

Phenotypes

For each study, WHR (waist circumference divided by hip circumference) was corrected for age, BMI, and genomic principal components (derived from GWAS data, the variants with MAF >1% on the ExomeChip, and ancestry informative markers available on the ExomeChip), as well as any additional study-specific covariates (e.g. recruiting center), in a linear regression model. For studies with unrelated individuals, residuals were calculated separately by sex, whereas for family-based studies sex was included as a covariate in models with both men and women. Residuals for case/control studies were calculated separately. Finally, residuals were inverse normal transformed and used as the outcome in association analyses. Phenotype descriptives by study are shown in Supplementary Data 3.

Genotypes and QC

The majority of studies followed a standardized protocol and performed genotype calling using the algorithms indicated in Supplementary Data 2, which typically included zCall³. For 10 studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, raw intensity data for samples from seven genotyping centers were combined for joint calling⁴. Study-specific quality control (QC) of the genotyped variants was implemented before association analysis (Supplementary Data 1–2). To assess whether any significant associations with rare and low-frequency variants could be due to allele calling in smaller studies, we performed a sensitivity meta-analysis of all large studies (>5,000 participants) compared to all studies. We found very high concordance for effect sizes, suggesting that smaller studies do not bias our results (Supplementary Fig. 24).

Study-level statistical analyses

Each cohort performed single variant analyses for both additive and recessive models in each ancestry, for sexes combined and sex-specific groups, with either RAREMETALWORKER (see URLs) or RVTESTs (see URLs). to associate inverse normal transformed WHRadjBMI with genotype accounting for cryptic relatedness (kinship matrix) in a linear mixed model. Both programs perform score-statistic rare-variant association analysis, accommodate unrelated and related individuals, and provide single-variant results and variance-covariance matrices. The covariance matrix captures linkage disequilibrium (LD) between markers within 1 Mb, which is used for gene-level meta-analyses and conditional analyses^{113,114}.

Centralized quality-control

Individual cohorts identified ancestry outliers based on 1000 Genomes Phase 1 reference populations. A centralized QC procedure implemented in EasyQC¹¹⁵ was applied to individual cohort summary statistics to identify cohort-specific problems: (1) possible errors

in phenotype residual transformation; (2) strand issues, and (3) inflation due to population stratification, cryptic relatedness and genotype biases.

Meta-analyses

Meta-analyses were carried out in parallel by two analysts at two sites using RAREMETAL¹¹³. We excluded variants if they had call rate <95%, Hardy-Weinberg equilibrium P-value $<1 \times 10^{-7}$, or large allele frequency deviations from reference populations (>0.6 for all ancestries analyses and >0.3 for ancestry-specific population analyses). We also excluded markers not present on the Illumina ExomeChip array 1.0, Y-chromosome and mitochondrial variants, indels, multiallelic markers, and problematic variants based on Blat-based sequence alignment. Significance for single-variant analyses was defined at an array-wide level ($P < 2 \times 10^{-7}$). For all suggestive significant variants ($P < 2 \times 10^{-6}$) from Stage 1, we calculated P_{sexhet} for each SNP, testing for differences between women-specific and men-specific beta estimates and standard errors using EasyStrata¹¹⁶. Each SNP that reached $P_{\text{sexhet}} < 0.05/\#$ of variants tested (70 variants brought forward from Stage 1, $P_{\text{sexhet}} < 7.14 \times 10^{-4}$) was considered significant. Additionally, while each individual study was asked to perform association analyses stratified by ancestry and adjusted for population stratification, all study-specific summary statistics were combined in our all ancestry meta-analyses. To investigate potential heterogeneity across ancestries, we examined ancestry-specific meta-analysis results for our top 70 variants from Stage 1 and found no evidence of significant across-ancestry heterogeneity for any of our top variants (I^2 values noted in Supplementary Data 4–6).

For the gene-based analyses, we applied two sets of criteria to select variants with a $\text{MAF} < 5\%$ within each ancestry based on coding variant annotation from five prediction algorithms (PolyPhen2, HumDiv and HumVar, LRT, MutationTaster, and SIFT)¹¹⁷. Our broad gene-based tests included nonsense, stop-loss, splice site, and missense variants annotated as damaging by at least one algorithm mentioned above. Our strict gene-based tests included only nonsense, stop-loss, splice site, and missense variants annotated as damaging by all five algorithms. These analyses were performed using the sequence kernel association test (SKAT) and variable threshold (VT) methods in RAREMETAL¹¹³. Statistical significance for gene-based tests was set at a Bonferroni-corrected threshold of $P < 2.5 \times 10^{-6}$ (0.05/~20,000 genes).

Genomic inflation

We observed marked genomic inflation of the test statistics even after controlling for population stratification arising mainly from common markers; λ_{GC} in the primary meta-analysis (combined ancestries and combined sexes) was 1.06 for all variants and 1.37 for common coding and splice site markers, respectively (Supplementary Figures 3, 7 and 13, Supplementary Table 10). Such inflation is expected for a highly polygenic trait like WHRadjBMI, for studies using a non-random set of variants across the genome, and is consistent with our very large sample size^{115,118,119}.

Conditional analyses

The RAREMETAL R-package¹¹³ was used to identify independent WHRadjBMI association signals across all ancestries and European meta-analysis results. RAREMETAL performs conditional analyses using covariance matrices to distinguish true signals from shadows of adjacent significant variants in LD. First, we identified lead variants ($P < 2 \times 10^{-7}$) based on a 1Mb window centered on the most significant variant. We then conditioned on the lead variants in RAREMETAL and kept new lead signals at $P < 2 \times 10^{-7}$ for conditioning in a second round of analysis. The process was repeated until no additional signal emerged below the pre-specified P-value threshold ($P < 2 \times 10^{-7}$).

To test if the associations detected were independent of previously published WHRadjBMI variants^{10,14,16}, we used RAREMETAL to perform conditional analyses in the Stage 1 discovery set if the GWAS variant or its proxy ($r^2 \geq 0.8$) was on the ExomeChip. All variants identified in our meta-analysis and the previously published variants were available in the UKBB dataset¹¹², which was used as a replacement dataset if a good proxy was not on the ExomeChip. All conditional analyses in the UKBB were performed using SNPTEST¹²⁰⁻¹²².

The conditional analyses were carried out reciprocally, conditioning on the ExomeChip variant and then the previously published variant. An association was considered independent if it was significant prior to conditional analysis ($P < 2 \times 10^{-7}$) with both the exome chip variant and the previously published variant, and the observed association with our variant remained significant upon conditional analysis. Conditional p-values between 9×10^{-6} and 0.05 was considered inconclusive, while those $< 9 \times 10^{-6}$ were considered suggestive.

Stage 2 meta-analyses

In Stage 2, we sought to validate 70 Stage 1 variants ($P < 2 \times 10^{-6}$) in two independent studies, UKBB (N=119,572) and deCODE (N=12,605), using the same QC and analytical methodology. Genotyping, study descriptions and phenotype descriptives are provided in Supplementary Data 1–3. Stage 1+2 meta-analysis was performed using the inverse-variance weighted fixed effects method. Significant associations were defined as those nominally significant ($P < 0.05$) in Stage 2 when available in Stage 2, and array-wide significance for Stage 1+2 at $P < 2 \times 10^{-7}$ ($0.05/\sim 250,000$ 246,328 variants tested). Variants are considered novel and statistically significant if they were greater than one megabase (Mb) from a previously-identified WHRadjBMI lead SNP¹⁰⁻¹⁶ and achieved a significance threshold of $P < 2 \times 10^{-7}$.

Pathway enrichment analyses: EC-DEPICT

We adapted DEPICT, a gene set enrichment analysis method for GWAS data, for use with the ExomeChip ('EC-DEPICT') described further in a companion manuscript²¹. DEPICT uses "reconstituted" gene sets, where different types of gene sets (e.g. canonical pathways, protein-protein interaction networks, and mouse phenotypes) were extended through large-scale microarray data (see Pers et al.²⁰ for details). EC-DEPICT computes p-values based on Swedish ExomeChip data (Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS), and Scania Diabetes Registry (SDR) cohorts, N=11,899) and, unlike DEPICT,

takes as input only genes directly containing significant (coding) variants rather than all genes within a specified LD (Supplementary Note).

Two analyses were performed for WHRadjBMI ExomeChip: one with all variants $p < 5 \times 10^{-4}$ (49 significant gene sets in 25 meta-gene sets, FDR < 0.05) and one with all variants > 1 Mb from known GWAS loci¹⁰ (26 significant gene sets in 13 meta-gene sets, FDR < 0.05). Affinity propagation clustering¹²³ was used to group highly correlated gene sets into “meta-gene sets”; for each meta-gene set, the member gene set with the best p-value was used for visualization (Supplementary Note). EC-DEPICT was written in Python (see URLs).

Pathway enrichment analyses: PASCAL

We also applied PASCAL pathway analysis²² to summary statistics from Stage 1 for all coding variants. PASCAL derives gene-based scores (SUM and MAX) and tests for over-representation of high gene scores in predefined biological pathways. We performed both MAX and SUM estimations for pathway enrichment. MAX is sensitive to genesets driven by a single signal, while SUM is better for multiple variant associations in the same gene. We used standard pathway libraries from KEGG, REACTOME and BIOCARTA, and also added dichotomized (Z -score > 3) reconstituted gene sets from DEPICT²⁰. To accurately estimate SNP-by-SNP correlations even for rare variants, we used the UK10K data (TwinsUK¹²⁴ and ALSPAC¹²⁵, $N=3781$). To distinguish contributions of regulatory and coding variants, we also applied PASCAL to summary statistics of only regulatory variants (20 kb upstream) and regulatory+coding variants from the Shungin et al¹⁰ study. In this way, we could investigate what is gained by analyzing coding variants.

Monogenic obesity enrichment analyses

We compiled two lists consisting of 31 genes with strong evidence that disruption causes monogenic forms of insulin resistance or diabetes; and eight genes with evidence that disruption causes monogenic forms of lipodystrophy. To test for association enrichment, we conducted simulations by matching each gene with others based on gene length and number of variants tested to create 1,000 matched gene sets and assessed how often the number of variants exceeding set significance thresholds was greater than in our monogenic obesity gene set.

Variance explained

We estimated phenotypic variance explained by Stage 1 associations in all ancestries for men, women, and combined sexes¹²⁶. For each associated region, we pruned subsets of SNPs within 500 kb of SNPs with the lowest P-value and used varying P-value thresholds (ranging from 2×10^{-7} to 0.02) from the combined sexes results. Additionally, we examined all variants and independent variants across a range of MAFs. The variance explained by each subset of SNPs in each stratum was estimated by summing the variance explained by individual top coding variants. To compare variance explained between men and women, we tested for significant differences assuming the weighted sum of χ^2 -distributed variables tend to a Gaussian distribution following Lyapunov's central limit theorem.^{126,127}

Cross-trait lookups

To evaluate relationships between WHRadjBMI and related cardiometabolic, anthropometric, and reproductive traits, association results for the 51 WHRadjBMI coding SNPs were requested from seven consortia, including ExomeChip data from GIANT (BMI, height), Global Lipids Genetics Consortium (GLGC) (total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol), International Consortium for Blood Pressure (IBPC)¹²⁸ (systolic and diastolic blood pressure), Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) (glycemic traits), and DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium (type 2 diabetes).^{21,25–29} For coronary artery disease, we accessed 1000 Genomes Project-imputed GWAS data released by CARDIoGRAMplusC4D¹²⁹ and for age at menarche and menopause, we used a combination of ExomeChip and 1000 Genomes Project-imputed GWAS data from ReproGen. Heatmaps were generated with gplots (R v3.3.2) using Euclidean distance based on p-value and direction of effect and complete linkage clustering (see URLs).

GWAS Catalog Lookups

To determine if significant coding variants were associated with any related cardiometabolic or anthropometric traits, we also searched the NHGRI-EBI GWAS Catalog for previous associations near our lead SNPs (\pm 500 kb). We used PLINK to calculate LD using ARIC European participants. All GWAS Catalog SNPs within the specified regions with an $r^2 > 0.7$ were evaluated³⁷. Consistent direction of effect was based on WHRadjBMI-increasing allele, LD, and allele frequency. We do not comment on direction of effect when a GWAS Catalog variant was not identical or in high LD ($r^2 > 0.9$) with the WHR variant, and MAF $> 45\%$.

Body-fat percentage associations

We performed body fat percent and truncal fat percent look-ups of 48 of the 56 WHRadjBMI identified variants (Tables 1 and 2) available in UKBB. GWAS for body fat percent and truncal fat percent in UKBB excluded pregnant or possibly pregnant women, individuals with BMI < 15 , or those without genetically confirmed European ancestry, resulting in a sample size of 120,286. Estimated body fat percent and truncal fat percent were obtained using the Tanita BC418MA body composition analyzer (Tanita, Tokyo, Japan). Participants were non-fasting and did not follow any specific instructions prior to bioimpedance measurements. SNPTTEST was used to perform the analyses based on residuals adjusted for age, 15 principal components, assessment center and the genotyping chip¹²⁰.

Collider bias

To evaluate SNPs for possible collider bias¹⁷, we used results from a recent GIANT BMI GWAS²⁵. For each significant SNP from our additive models, WHRadjBMI associations

URLS

Ensembl ortholog database, <http://www.ensembl.org>; RAREMETALWORKER, <http://genome.sph.umich.edu/wiki/RAREMETALWORKER>; RVTESTs, <http://zhanxw.github.io/rvtests/>; EC-DEPICT, code available at: <https://github.com/RebeccaFine/obesity-ec-depict>; gplots, <https://CRAN.R-project.org/package=gplots>.

were corrected for potential bias due to associations between each variant and BMI (Supplementary Note). Variants meeting Bonferroni-corrected significance ($P_{\text{corrected}} < 9.09 \times 10^{-4}$, 0.05/55 variants examined) were considered robust against collider bias.

Drosophila RNAi knockdown experiments

For each gene with WHRadjBMI-associated coding variants in the final combined meta-analysis ($P < 2 \times 10^{-7}$), its corresponding *Drosophila* orthologues were identified in the Ensembl ortholog database (see URLs), when available. *Drosophila* triglyceride content values were mined from a publicly available genome-wide fat screen data set⁴⁵ to identify potential genes for follow-up knockdowns. Estimated values represent fractional changes in triglyceride content in adult male flies. Data are from male progeny of crosses between male UAS-RNAi flies from the Vienna *Drosophila* Resource Center (VDRC) and Hsp70-GAL4; Tub-GAL8ts virgin females. (Supplementary Note). The screen comprised one to three biological replicates. We followed up each gene with a >0.2 increase or >0.4 decrease in triglyceride content.

Orthologues for two genes were brought forward for follow-up, *DNAH10* and *PLXND1*. For both genes, we generated adipose tissue (cg-Gal4) and neuronal (elav-Gal4) specific RNAi-knockdown crosses to knockdown transcripts in a tissue specific manner, leveraging upstream activation sequence (UAS)-inducible short-hairpin knockdown lines, available through the VDRC (Vienna *Drosophila* Resource Center). Specifically, elav-Gal4, which drives expression of the RNAi construct in post mitotic neurons starting at embryonic stages all the way to adulthood, was used. Cg drives expression in the fat body and hemocytes starting at embryonic stage 12, all the way to adulthood. (Supplementary Note). Resulting triglyceride values were normalized to fly weight and larval/population density. We used the non-parametric Kruskal-Wallis test to compare wild type with knockdown lines.

Expression quantitative trait loci (eQTLs) analysis

We queried the significant variant (Exome coding SNPs)-gene pairs associated with eGenes across five metabolically relevant tissues (skeletal muscle, subcutaneous adipose, visceral adipose, liver and pancreas) with at least 70 samples in the GTEx database⁴⁶. For each tissue, variants were selected based on the following thresholds: the minor allele was observed in at least 10 samples, and MAF $\geq 1\%$. eGenes, genes with a significant eQTL, are defined on a false discovery rate (FDR)¹³⁰ threshold of 0.05 of beta distribution-adjusted empirical p-value from FastQTL. Nominal p-values were generated for each variant-gene pair by testing the alternative hypothesis that the slope of a linear regression model between genotype and expression deviates from 0. To identify all significant variant-gene pairs associated with eGenes, a genome-wide empirical p-value threshold⁶⁴ (pt) was defined as the empirical p-value of the gene closest to the 0.05 FDR threshold. pt was then used to calculate a nominal p-value threshold for each gene based on the beta distribution model (from FastQTL) of the minimum p-value distribution $f(\text{pmin})$ obtained from the permutations for the gene. For each gene, variants with a nominal p-value below the gene-level threshold were considered significant and included in the final list of variant-gene pairs⁶⁴. For each eGene, we also listed the most significantly associated variants (eSNP).

Only these exome SNPs with $r^2 > 0.8$ with eSNPs were considered for biological interpretation (Supplementary eQTL GTEx).

We also performed cis-eQTL analysis in 770 METSIM subcutaneous adipose tissue samples as described in Civelek, et al.¹³¹ A false discovery rate (FDR) was calculated using all p-values from the cis-eQTL detection in the q-value package in R. Variants associated with nearby genes at an FDR less than 1% were considered to be significant (equivalent p-value $< 2.46 \times 10^{-4}$).

For loci with more than one microarray probeset of the same gene associated with the exome variant, we selected the probeset that provided the strongest LD r^2 between the exome variant and the eSNP. In reciprocal conditional analysis, we conditioned on the lead exome variant by including it as a covariate in the cis-eQTL detection and reporting the p-value of the eSNP and vice versa. Signals were considered coincident if both the lead exome variant and the eSNP were no longer significant after conditioning on the other and the variants were in high LD ($r^2 > 0.80$).

For loci that also harbored reported GWAS variants, we performed reciprocal conditional analysis between the GWAS lead variant and the lead eSNP. For loci with more than one reported GWAS variant, the GWAS variant with the strongest LD r^2 with the lead eSNP was reported.

Penetrance analysis

Phenotype and genotype data from UKBB were used for penetrance analysis. Three of 16 rare and low frequency variants (MAF $< 1\%$) detected in the final Stage 1+2 meta-analysis were available in UKBB and had relatively larger effect sizes (>0.90). Phenotype data for these three variants were stratified by WHR using World Health Organization (WHO) guidelines, which consider women and men with WHR greater than 0.85 and 0.90 as obese, respectively. Genotype and allele counts were used to calculate the number of carriers of the minor allele. The number of obese vs. non-obese carriers for women, men and sexes combined was compared using a χ^2 test. Significance was determined using a Bonferroni correction for the number of tests performed ($0.05/9=5.5 \times 10^{-3}$).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Anne E Justice^{*,1,2}, Tugce Karaderi^{*,3,4}, Heather M Highland^{*,1,5}, Kristin L Young^{*,1}, Mariaelisa Graff^{*,1}, Yingchang Lu^{*,6,7,8}, Valérie Turcot^{*,9}, Paul L Auer¹⁰, Rebecca S Fine^{11,12,13}, Xiuqing Guo¹⁴, Claudia Schurmann^{7,8}, Adelheid Lempradl¹⁵, Eirini Marouli¹⁶, Anubha Mahajan³, Thomas W Winkler¹⁷, Adam E Locke^{18,19}, Carolina Medina-Gomez^{20,21}, Tõnu Esko^{11,13,22}, Sailaja Vedantam^{11,12,13}, Ayush Giri²³, Ken Sin Lo^{9,23}, Tamuno Alfred⁷, Poorva Mudgal²⁴, Maggie CY Ng^{24,25}, Nancy L Heard-Costa^{26,27}, Mary F Feitosa²⁸, Alisa K Manning^{11,29,30}, Sara M Willems³¹, Suthesh

Sivapalaratnam^{30,32,33}, Goncalo Abecasis^{18,34}, Dewan S Alam³⁵, Matthew Allison³⁶, Philippe Amouyel^{37,38,39}, Zorayr Arzumanyan¹⁴, Beverley Balkau⁴⁰, Lisa Bastarache⁴¹, Sven Bergmann^{42,43}, Lawrence F Bielak⁴⁴, Matthias Blüher^{45,46}, Michael Boehnke¹⁸, Heiner Boeing⁴⁷, Eric Boerwinkle^{5,48}, Carsten A Böger⁴⁹, Jette Bork-Jensen⁵⁰, Erwin P Bottinger⁷, Donald W Bowden^{24,25,51}, Ivan Brandslund^{52,53}, Linda Broer²¹, Amber A Burt⁵⁴, Adam S Butterworth^{55,56}, Mark J Caulfield^{16,57}, Giancarlo Cesana⁵⁸, John C Chambers^{59,60,61,62,63}, Daniel I Chasman^{11,64,65,66}, Yii-Der Ida Chen¹⁴, Rajiv Chowdhury⁵⁵, Cramer Christensen⁶⁷, Audrey Y Chu⁶⁵, Francis S Collins⁶⁸, James P Cook⁶⁹, Amanda J Cox^{24,25,70}, David S Crosslin⁷¹, John Danesh^{55,56,72,73}, Paul IW de Bakker^{74,75}, Simon de Denus^{9,76}, Renée de Mutsert⁷⁷, George Dedoussis⁷⁸, Ellen W Demerath⁷⁹, Joe G Dennis⁸⁰, Josh C Denny⁴¹, Emanuele Di Angelantonio^{55,56,73}, Marcus Dörr^{81,82}, Fotios Drenos^{83,84,85}, Marie-Pierre Dubé^{9,86}, Alison M Dunning⁸⁷, Douglas F Easton^{80,87}, Paul Elliott⁸⁸, Evangelos Evangelou^{61,89}, Aliko-Eleni Farmaki⁷⁸, Shuang Feng¹⁸, Ele Ferrannini^{90,91}, Jean Ferrieres⁹², Jose C Florez^{11,29,30}, Myriam Fornage⁹³, Caroline S Fox²⁷, Paul W Franks^{94,95,96}, Nele Friedrich⁹⁷, Wei Gan³, Ilaria Gandin⁹⁸, Paolo Gasparini^{99,100}, Vilmantas Giedraitis¹⁰¹, Giorgia Grotto^{99,100}, Mathias Gorski^{17,49}, Harald Grallert^{102,103,104}, Niels Grarup⁵⁰, Megan L Grove⁵, Stefan Gustafsson¹⁰⁵, Jeff Haessler¹⁰⁶, Torben Hansen⁵⁰, Andrew T Hattersley¹⁰⁷, Caroline Hayward¹⁰⁸, Iris M Heid^{17,109}, Oddgeir L Holmen¹¹⁰, G Kees Hovingh¹¹¹, Joanna MM Howson⁵⁵, Yao Hu¹¹², Yi-Jen Hung^{113,114}, Kristian Hveem^{110,115}, M Arfan Ikram^{20,116,117}, Erik Ingelsson^{105,118}, Anne U Jackson¹⁸, Gail P Jarvik^{54,119}, Yucheng Jia¹⁴, Torben Jørgensen^{120,121,122}, Pekka Jousilahti¹²³, Johanne M Justesen⁵⁰, Bratati Kahali^{124,125,126,127}, Maria Karaleftheri¹²⁸, Sharon LR Kardia⁴⁴, Fredrik Karpe^{129,130}, Frank Kee¹³¹, Hidetoshi Kitajima³, Pirjo Komulainen¹³², Jaspal S Kooner^{60,62,63,133}, Peter Kovacs⁴⁵, Bernhard K Krämer¹³⁴, Kari Kuulasmaa¹²³, Johanna Kuusisto¹³⁵, Markku Laakso¹³⁵, Timo A Lakka^{132,136,137}, David Lamparter^{42,43,138}, Leslie A Lange¹³⁹, Claudia Langenberg³¹, Eric B Larson^{54,140,141}, Nanette R Lee^{142,143}, Wen-Jane Lee^{144,145}, Terho Lehtimäki^{146,147}, Cora E Lewis¹⁴⁸, Huaixing Li¹¹², Jin Li¹⁴⁹, Ruifang Li-Gao⁷⁷, Li-An Lin⁹³, Xu Lin¹¹², Lars Lind¹⁵⁰, Jaana Lindström¹²³, Allan Linneberg^{122,151,152}, Ching-Ti Liu¹⁵³, Dajiang J Liu¹⁵⁴, Jian'an Luan³¹, Leo-Pekka Lyytikäinen^{146,147}, Stuart MacGregor¹⁵⁵, Reedik Mägi²², Satu Männistö¹²³, Gaëlle Marenne⁷², Jonathan Marten¹⁰⁸, Nicholas GD Masca^{156,157}, Mark I McCarthy^{3,129,130}, Karina Meidtner^{102,158}, Evelin Mihailov²², Leena Moilanen¹⁵⁹, Marie Moitry^{160,161}, Dennis O Mook-Kanamori^{77,162}, Anna Morgan⁹⁹, Andrew P Morris^{3,69}, Martina Müller-Nurasyid^{109,163,164}, Patricia B Munroe^{16,57}, Narisu Narisu⁶⁸, Christopher P Nelson^{156,157}, Matt Neville^{129,130}, Ioanna Ntalla¹⁶, Jeffrey R O'Connell¹⁶⁵, Katharine R Owen^{129,130}, Oluf Pedersen⁵⁰, Gina M Peloso¹⁵³, Craig E Pennell^{166,167}, Markus Perola^{123,168}, James A Perry¹⁶⁵, John RB Perry³¹, Tune H Pers^{50,169}, Ailith Ewing⁸⁰, Ozren Polasek^{170,171}, Olli T Raitakari^{172,173}, Asif Rasheed¹⁷⁴, Chelsea K Raulerson¹⁷⁵, Rainer Rauramaa^{132,136}, Dermot F Reilly¹⁷⁶, Alex P Reiner^{106,177}, Paul M Ridker^{65,66,178}, Manuel A Rivas¹⁷⁹, Neil R Robertson^{3,129}, Antonietta Robino¹⁸⁰, Igor Rudan¹⁷¹, Katherine S Ruth¹⁸¹, Danish Saleheen^{174,182}, Veikko Salomaa¹²³, Nilesh J Samani^{156,157}, Pamela J

Schreiner¹⁸³, Matthias B Schulze^{102,158}, Robert A Scott³¹, Marcelo Segura-Lepe⁶¹, Xueling Sim^{18,184}, Andrew J Slater^{185,186}, Kerrin S Small¹⁸⁷, Blair H Smith^{188,189}, Jennifer A Smith⁴⁴, Lorraine Southam^{3,72}, Timothy D Spector¹⁸⁷, Elizabeth K Speliotes^{124,125,126}, Kari Stefansson^{190,191}, Valgerdur Steinthorsdottir¹⁹⁰, Kathleen E Stirrups^{16,33}, Konstantin Strauch^{109,192}, Heather M Stringham¹⁸, Michael Stumvoll^{45,46}, Liang Sun¹¹², Praveen Surendran⁵⁵, Karin MA Swart¹⁹³, Jean-Claude Tardif^{9,86}, Kent D Taylor¹⁴, Alexander Teumer¹⁹⁴, Deborah J Thompson⁸⁰, Gudmar Thorleifsson¹⁹⁰, Unnur Thorsteinsdottir^{190,191}, Betina H Thuesen¹²², Anke Tönjes¹⁹⁵, Mina Torres¹⁹⁶, Emmanouil Tsafantakis¹⁹⁷, Jaakko Tuomilehto^{123,198,199,200}, André G Uitterlinden^{20,21}, Matti Uusitupa²⁰¹, Cornelia M van Duijn²⁰, Mauno Vanhala^{202,203}, Rohit Varma¹⁹⁶, Sita H Vermeulen²⁰⁴, Henrik Vestergaard^{50,205}, Veronique Vitart¹⁰⁸, Thomas F Vogt²⁰⁶, Dragana Vuckovic^{99,100}, Lynne E Wagenknecht²⁰⁷, Mark Walker²⁰⁸, Lars Wallentin²⁰⁹, Feijie Wang¹¹², Carol A Wang^{166,167}, Shuai Wang¹⁵³, Nicholas J Wareham³¹, Helen R Warren^{16,57}, Dawn M Waterworth²¹⁰, Jennifer Wessel²¹¹, Harvey D White²¹², Cristen J Willer^{124,125,213}, James G Wilson²¹⁴, Andrew R Wood¹⁸¹, Ying Wu¹⁷⁵, Hanieh Yaghootkar¹⁸¹, Jie Yao¹⁴, Laura M Yerges-Armstrong^{165,215}, Robin Young^{55,216}, Eleftheria Zeggini⁷², Xiaowei Zhan²¹⁷, Weihua Zhang^{60,61}, Jing Hua Zhao³¹, Wei Zhao¹⁸², He Zheng¹¹², Wei Zhou^{124,125}, M Carola Zillikens^{20,21}, CHD Exome+ Consortium²¹⁸, Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium²¹⁸, EPIC-CVD Consortium²¹⁸, ExomeBP Consortium²¹⁸, Global Lipids Genetic Consortium²¹⁸, GoT2D Genes Consortium²¹⁸, InterAct²¹⁸, ReproGen Consortium²¹⁸, T2D-Genes Consortium²¹⁸, The MAGIC Investigators²¹⁸, Fernando Rivadeneira^{20,21}, Ingrid B Borecki²⁸, J. Andrew Pospisilik¹⁵, Panos Deloukas^{16,219}, Timothy M Frayling¹⁸¹, Guillaume Lettre^{9,86}, Karen L Mohlke¹⁷⁵, Jerome I Rotter¹⁴, Zoltán Kutalik^{43,220}, Joel N Hirschhorn^{11,13,221}, L Adrienne Cupples^{1,27,153}, Ruth JF Loos^{1,7,8,222}, Kari E North^{1,223}, and Cecilia M Lindgren^{1,*,3,224}

Affiliations

¹Department of Epidemiology, University of North Carolina, Chapel Hill, NC, 27514, USA ²Weis Center for Research, Geisinger Health System, Danville, PA 17822 ³Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK ⁴Department of Biological Sciences, Faculty of Arts and Sciences, Eastern Mediterranean University, Famagusta, Cyprus ⁵Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA ⁶Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, 37203, USA ⁷The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA ⁸The Genetics of Obesity and Related Metabolic Traits Program, Icahn School of Medicine at Mount Sinai, New York, NY, 10069, USA ⁹Montreal Heart Institute, Université de Montréal, Montreal, Quebec, H1T 1C8, Canada ¹⁰Zilber School of Public Health, University of Wisconsin-Milwaukee,

Milwaukee, WI, 53201, USA ¹¹.Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA ¹².Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA ¹³.Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's Hospital, Boston, MA, 02115, USA ¹⁴.Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, 90502, USA ¹⁵.Max Planck Institute of Immunobiology and Epigenetics, Freiburg, 79108, Germany ¹⁶.William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, EC1M 6BQ, UK ¹⁷.Department of Genetic Epidemiology, University of Regensburg, Regensburg, D-93051, Germany ¹⁸.Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, 48109, USA ¹⁹.McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO, 63108, USA ²⁰.Department of Epidemiology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands ²¹.Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands ²².Estonian Genome Center, University of Tartu, Tartu, 51010, Estonia ²³.Department of Obstetrics and Gynecology, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN, 37203, USA ²⁴.Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA ²⁵.Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA ²⁶.Department of Neurology, Boston University School of Medicine, Boston, MA, 02118, USA ²⁷.NHLBI Framingham Heart Study, Framingham, MA, 01702, USA ²⁸.Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, MO, 63108, USA ²⁹.Department of Medicine, Harvard University Medical School, Boston, MA, 02115, USA ³⁰.Massachusetts General Hospital, Boston, MA, 02114, USA ³¹.MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, CB2 0QQ, UK ³².Department of Vascular Medicine, AMC, Amsterdam, 1105 AZ, The Netherlands ³³.Department of Haematology, University of Cambridge, Cambridge, CB2 0PT, UK ³⁴.School of Public Health, University of Michigan, Ann Arbor, MI, 48109, USA ³⁵.School of Kinesiology and Health Science, Faculty of Health, York University, Toronto ³⁶.Department of Family Medicine & Public Health, University of California, San Diego, La Jolla, CA, 92093, USA ³⁷.INSERM U1167, Lille, F-59019, France ³⁸.Institut Pasteur de Lille, U1167, Lille, F-59019, France ³⁹.Universite de Lille, U1167 - RID-AGE - Risk factors and molecular determinants of aging-related diseases, Lille, F-59019, France ⁴⁰.INSERM U1018, Centre de recherche en Épidémiologie et Santé des Populations (CESP), Villejuif, France ⁴¹.Department of Biomedical Informatics, Vanderbilt University, Nashville, TN, 37203, USA ⁴².Department of Computational Biology, University of Lausanne, Lausanne, 1011, Switzerland ⁴³.Swiss Institute of Bioinformatics, Lausanne, 1015, Switzerland ⁴⁴.Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, 48109, USA ⁴⁵.IFB Adiposity Diseases, University of Leipzig, Leipzig, 04103, Germany ⁴⁶.University of Leipzig, Department of Medicine,

Leipzig, 04103, Germany ⁴⁷.Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, 14558, Germany ⁴⁸.Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030 USA ⁴⁹.Department of Nephrology, University Hospital Regensburg, Regensburg, 93042, Germany ⁵⁰.The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2100, Denmark ⁵¹.Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA ⁵².Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, 7100, Denmark ⁵³.Institute of Regional Health Research, University of Southern Denmark, Odense, 5000, Denmark ⁵⁴.Department of Medicine (Medical Genetics), University of Washington, Seattle, WA, 98195, USA ⁵⁵.MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK ⁵⁶.NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK ⁵⁷.NIHR Barts Cardiovascular Research Centre, Barts and The London School of Medicine & Dentistry, 162 Queen Mary University of London, London, EC1M 6BQ, UK ⁵⁸.Research Centre on Public Health, University of Milano-Bicocca, Monza, 20900, Italy ⁵⁹.Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore ⁶⁰.Department of Cardiology, London North West Healthcare NHS Trust, Ealing Hospital, Middlesex, UB1 3HW, UK ⁶¹.Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK ⁶².Imperial College Healthcare NHS Trust, London, W12 0HS, UK ⁶³.MRC-PHE Centre for Environment and Health, Imperial College London, London, W2 1PG, UK ⁶⁴.Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA ⁶⁵.Division of Preventive Medicine, Brigham and Women's and Harvard Medical School, Boston, MA, 02215, USA ⁶⁶.Harvard Medical School, Boston, MA, 02115, USA ⁶⁷.Medical department, Lillebaelt Hospital, Vejle, 7100, Denmark ⁶⁸.Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA ⁶⁹.Department of Biostatistics, University of Liverpool, Liverpool, L69 3GL, UK ⁷⁰.Menzies Health Institute Queensland, Griffith University, Southport, QLD, Australia ⁷¹.Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, 98195, USA ⁷².Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK ⁷³.British Heart Foundation Cambridge Centre of Excellence, Department of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK ⁷⁴.Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands ⁷⁵.Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands ⁷⁶.Faculty of Pharmacy, Universite de Montreal, Montreal, Quebec, H3T 1J4, Canada ⁷⁷.Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, 2300RC, The Netherlands ⁷⁸.Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, 17671, Greece ⁷⁹.Division of Epidemiology & Community Health,

School of Public Health, University of Minnesota, Minneapolis, MN, 55454, USA
⁸⁰.Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK ⁸¹.Department of Internal Medicine B, University Medicine Greifswald, Greifswald, 17475, Germany
⁸².DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Greifswald, 17475, Germany ⁸³.Institute of Cardiovascular Science, University College London, London, WC1E 6JF, UK ⁸⁴.MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, BS8 2BN, UK ⁸⁵.Department of Life Sciences, Brunel University London, Uxbridge, UB8 3PH, UK ⁸⁶.Department of Medicine, Faculty of Medicine, Université de Montréal, Montréal, Québec, H3T 1J4, Canada ⁸⁷.Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK
⁸⁸.Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, W2 1PG, UK ⁸⁹.Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, 45110, Greece ⁹⁰.CNR Institute of Clinical Physiology, Pisa, Italy
⁹¹.Department of Clinical & Experimental Medicine, University of Pisa, Italy
⁹².Toulouse University School of Medicine, Toulouse, TSA 50032 31059, France
⁹³.Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA ⁹⁴.Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, SE-20502, Sweden
⁹⁵.Department of Nutrition, Harvard School of Public Health, Boston, MA, 02115, USA ⁹⁶.Department of Public Health and Clinical Medicine, Unit of Medicine, Umeå University, Umeå, 901 87, Sweden ⁹⁷.Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, 17475, Germany ⁹⁸.Ilaria Gandin, Research Unit, AREA Science Park, Trieste, 34149, Italy ⁹⁹.Department of Medical Sciences, University of Trieste, Trieste, 34137, Italy ¹⁰⁰.Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy ¹⁰¹.Geriatrics, Department of Public Health, Uppsala University, Uppsala, 751 85, Sweden ¹⁰².German Center for Diabetes Research, München-Neuherberg, 85764, Germany ¹⁰³.Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, 85764, Germany ¹⁰⁴.Research Unit of Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, 85764, Germany ¹⁰⁵.Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, 751 41, Sweden ¹⁰⁶.Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle WA, 98109, USA ¹⁰⁷.University of Exeter Medical School, University of Exeter, Exeter, EX2 5DW, UK ¹⁰⁸.MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK ¹⁰⁹.Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, 85764, Germany ¹¹⁰.K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health, NTNU, Norwegian University of Science and Technology, Trondheim, 7600, Norway ¹¹¹.AMC, Department of Vascular Medicine,

Amsterdam, 1105 AZ, The Netherlands ¹¹².CAS Key Laboratory of Nutrition, Metabolism and Food safety, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China ¹¹³.Division of Endocrinology and Metabolism, Department of Internal Medicine, Tri-Service General Hospital Songshan Branch, Taipei, Taiwan 11 ¹¹⁴.School of Medicine, National Defense Medical Center, Taipei, Taiwan 114, Taiwan ¹¹⁵.HUNT Research center, Department of Public Health, Norwegian University of Science and Technology, Levanger, 7600, Norway ¹¹⁶.Department of Neurology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands ¹¹⁷.Department of Radiology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands ¹¹⁸.Stanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA ¹¹⁹.Department of Genome Sciences, University of Washington, Seattle, WA, 98195, USA ¹²⁰.Faculty of medicine, Aalborg University, Aalborg, DK-9000, Denmark ¹²¹.Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark ¹²².Research Center for Prevention and Health, Capital Region of Denmark, Glostrup, DK-2600, Denmark ¹²³.National Institute for Health and Welfare, Helsinki, FI-00271, Finland ¹²⁴.Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA ¹²⁵.Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA ¹²⁶.Division of Gastroenterology, University of Michigan, Ann Arbor, MI, 48109, USA ¹²⁷.Centre for Brain Research, Indian Institute of Science, Bangalore 560012, India ¹²⁸.Echinos Medical Centre, Echinos, Greece ¹²⁹.Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LE, UK ¹³⁰.Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, OX3 7LE, UK ¹³¹.UKCRC Centre of Excellence for Public Health Research, Queens University Belfast, Belfast, UK, BT12 6BJ, UK ¹³².Foundation for Research in Health Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, 70100, Finland ¹³³.National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, London, W12 0NN, UK ¹³⁴.University Medical Centre Mannheim, 5th Medical Department, University of Heidelberg, Mannheim, 68167, Germany ¹³⁵.Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, 70210, Finland ¹³⁶.Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio Campus, 70210, Finland ¹³⁷.Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland ¹³⁸.Verge Genomics, San Fransico, CA, USA ¹³⁹.Division of Biomedical and Personalized Medicine, Department of Medicine, University of Colorado-Denver, Aurora, CO, 80045, USA ¹⁴⁰.Kaiser Permanente Washington Health Research Institute Seattle WA 98101 ¹⁴¹.Department of Health Services, University of Washington, Seattle WA 98101 ¹⁴².Department of Anthropology, Sociology, and History, University of San Carlos, Cebu City, 6000, Philippines ¹⁴³.USC-Office of Population Studies Foundation, Inc., University of San Carlos, Cebu City, 6000, Philippines ¹⁴⁴.Department of Medical Research, Taichung

Veterans General Hospital, Taichung, Taiwan 407, Taiwan ¹⁴⁵.Department of Social Work, Tunghai University, Taichung, Taiwan ¹⁴⁶.Department of Clinical Chemistry, Fimlab Laboratories, Tampere, 33521, Finland ¹⁴⁷.Department of Clinical Chemistry, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere 33014, Finland ¹⁴⁸.Division of Preventive Medicine University of Alabama at Birmingham, Birmingham, AL 35205, USA ¹⁴⁹.Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA, 94304, USA ¹⁵⁰.Uppsala University, Uppsala, 75185, Sweden ¹⁵¹.Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, DK-2000, Frederiksberg, Denmark ¹⁵².Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark ¹⁵³.Department of Biostatistics, Boston University School of Public Health, Boston, MA, 02118, USA ¹⁵⁴.Department of Public Health Sciences, Institute for Personalized Medicine, the Pennsylvania State University College of Medicine, Hershey, PA, 17033, USA ¹⁵⁵.QIMR Berghofer Medical Research Institute, Brisbane, Queensland, 4006, Australia ¹⁵⁶.Department of Cardiovascular Sciences, Univeristy of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK ¹⁵⁷.NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, LE3 9QP, UK ¹⁵⁸.Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, 14558, Germany ¹⁵⁹.Department of Medicine, Kuopio University Hospital, Kuopio, 70210, Finland ¹⁶⁰.Department of Epidemiology and Public Health, University of Strasbourg, Strasbourg, F-67085, France ¹⁶¹.Department of Public Health, University Hospital of Strasbourg, Strasbourg, F-67091, France ¹⁶².Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, 2300RC, The Netherlands ¹⁶³.Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universitat, Munich, 81377, Germany ¹⁶⁴.DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, 80802, Germany ¹⁶⁵.Program for Personalized and Genomic Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, 21201, US ¹⁶⁶.Division of Obstetric and Gynaecology, School of Medicine, The University of Western Australia, Perth, Western Australia, 6009, Australia ¹⁶⁷.School of Medicine and Public Health, Faculty of Medicine and Health, The University of Newcastle, Newcastle, New South Wales, 2308, Australia ¹⁶⁸.University of Helsinki, Institute for Molecular Medicine (FIMM) and Diabetes and Obesity Research Program, Helsinki, FI00014, Finland ¹⁶⁹.Department of Epidemiology Research, Statens Serum Institut, Copenhagen, 2200, Denmark ¹⁷⁰.School of Medicine, University of Split, Split, 21000, Croatia ¹⁷¹.Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH8 9AG, UK ¹⁷².Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, 20521, Finland ¹⁷³.Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, 20520, Finland ¹⁷⁴.Centre for Non-Communicable Diseases, Karachi, Pakistan ¹⁷⁵.Department of Genetics,

University of North Carolina, Chapel Hill, NC, 27599, USA ¹⁷⁶Merck & Co., Inc., Genetics and Pharmacogenomics, Boston, MA, 02115, USA ¹⁷⁷Department of Epidemiology, University of Washington, Seattle, WA, 98195, USA ¹⁷⁸Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA ¹⁷⁹Department of Biomedical Data Science, Stanford University, Stanford, California 94305 ¹⁸⁰Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, 34137, Italy ¹⁸¹Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, EX2 5DW, UK ¹⁸²Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA ¹⁸³Division of Epidemiology & Community Health University of Minnesota, Minneapolis, MN, 55454, USA ¹⁸⁴Saw Swee Hock School of Public Health, National University Health System, National University of Singapore, Singapore 117549, Singapore ¹⁸⁵Genetics, Target Sciences, GlaxoSmithKline, Research Triangle Park, NC, 27709, US ¹⁸⁶OmicSoft a QIAGEN Company, Cary, NC, 27513, US ¹⁸⁷Department of Twin Research and Genetic Epidemiology, King's College London, London, SE1 7EH, UK ¹⁸⁸Division of Population Health Sciences, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK ¹⁸⁹Generation Scotland, Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK ¹⁹⁰deCODE Genetics/Amgen inc., Reykjavik, 101, Iceland ¹⁹¹Faculty of Medicine, University of Iceland, Reykjavik, 101, Iceland ¹⁹²Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, 81377, Germany ¹⁹³VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam, 1007 MB, The Netherlands ¹⁹⁴Institute for Community Medicine, University Medicine Greifswald, Greifswald, 17475, Germany ¹⁹⁵Center for Pediatric Research, Department for Women's and Child Health, University of Leipzig, Leipzig, 04103, Germany ¹⁹⁶USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, 90033, USA ¹⁹⁷Anogia Medical Centre, Anogia, Greece ¹⁹⁸Centre for Vascular Prevention, Danube-University Krems, Krems, 3500, Austria ¹⁹⁹Dasman Diabetes Institute, Dasman, 15462, Kuwait ²⁰⁰Diabetes Research Group, King Abdulaziz University, Jeddah, 21589, Saudi Arabia ²⁰¹Department of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, 70210, Finland ²⁰²Central Finland Central Hospital, Jyväskylä, 40620, Finland ²⁰³University of Eastern Finland, Kuopio, 70210, Finland ²⁰⁴Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, 6500 HB, The Netherlands ²⁰⁵Steno Diabetes Center Copenhagen, Gentofte, 2800, Denmark ²⁰⁶Merck & Co., Inc., Cardiometabolic Disease, Kenilworth, NJ, 07033, USA ²⁰⁷Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA ²⁰⁸Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle, NE2 4HH, UK ²⁰⁹Department of Medical Sciences, Cardiology, Uppsala Clinical Research Center, Uppsala University, Uppsala, 752 37, Sweden ²¹⁰Genetics, Target Sciences, GlaxoSmithKline, Collegeville, PA ²¹¹Departments of Epidemiology & Medicine, Diabetes Translational Research Center, Fairbanks

School of Public Health & School of Medicine, Indiana University, Indiana, IN, 46202, USA ²¹².Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, Auckland, New Zealand ²¹³.Department of Human Genetics, University of Michigan, Ann Arbor, MI, 48109, USA ²¹⁴.Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, 39216, USA ²¹⁵.GlaxoSmithKline, King of Prussia, PA, 19406, USA ²¹⁶.University of Glasgow, Glasgow, G12 8QQ, UK ²¹⁷.Department of Clinical Sciences, Quantitative Biomedical Research Center, Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA ²¹⁸.A full list of contributing consortium members can be found in the Supplementary Note. ²¹⁹.Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King Abdulaziz University, Jeddah, 21589, Saudi Arabia ²²⁰.Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, 1010, Switzerland ²²¹.Departments of Pediatrics and Genetics, Harvard Medical School, Boston, MA, 02115, USA ²²².The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, 10069, USA ²²³.Department of Epidemiology and Carolina Center of Genome Sciences, Chapel Hill, NC, 27514, USA ²²⁴.Li Ka Shing Centre for Health Information and Discovery, The Big Data Institute, University of Oxford, Oxford, OX3 7BN, UK

ACKNOWLEDGEMENTS

This work was primarily supported through funding from the National Institute of Health (NIH): 1K99HL130580, R01-DK089256, 2R01HD057194, U01HG007416, R01DK101855, T32 HL007055, KL2TR001109; and the American Heart Association (AHA): 13POST16500011 and 13GRNT16490017. Co-author Yucheng Jia recently passed away while this work was in process. This study was completed as part of the Genetic Investigation of ANthropometric Traits (GIANT) Consortium. This research has been conducted using the UK Biobank resource. A full list of acknowledgements is provided in the Supplementary Data 18.

REFERENCES

1. Pischon T et al. General and abdominal adiposity and risk of death in Europe. *N Engl J Med* 359, 2105–20 (2008). [PubMed: 19005195]
2. Wang Y, Rimm EB, Stampfer MJ, Willett WC & Hu FB Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. *Am J Clin Nutr* 81, 555–63 (2005). [PubMed: 15755822]
3. Canoy D Distribution of body fat and risk of coronary heart disease in men and women. *Curr Opin Cardiol* 23, 591–8 (2008). [PubMed: 18830075]
4. Snijder MB et al. Associations of hip and thigh circumferences independent of waist circumference with the incidence of type 2 diabetes: the Hoorn Study. *Am J Clin Nutr* 77, 1192–7 (2003). [PubMed: 12716671]
5. Yusuf S et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. *Lancet* 366, 1640–9 (2005). [PubMed: 16271645]
6. Mason C, Craig CL & Katzmarzyk PT Influence of central and extremity circumferences on all-cause mortality in men and women. *Obesity (Silver Spring)* 16, 2690–5 (2008). [PubMed: 18927548]
7. Karpe F & Pinnick KE Biology of upper-body and lower-body adipose tissue--link to whole-body phenotypes. *Nat Rev Endocrinol* 11, 90–100 (2015). [PubMed: 25365922]

8. Manolopoulos KN, Karpe F & Frayn KN Gluteofemoral body fat as a determinant of metabolic health. *Int J Obes (Lond)* 34, 949–59 (2010). [PubMed: 20065965]
9. Emdin CA et al. Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. *JAMA* 317, 626–634 (2017). [PubMed: 28196256]
10. Shungin D et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature* 518, 187–96 (2015). [PubMed: 25673412]
11. Winkler TW et al. The Influence of Age and Sex on Genetic Associations with Adult Body Size and Shape: A Large-Scale Genome-Wide Interaction Study. *PLoS Genet* 11, e1005378 (2015).
12. Wen W et al. Genome-wide association studies in East Asians identify new loci for waist-hip ratio and waist circumference. *Sci Rep* 6, 17958 (2016). [PubMed: 26785701]
13. Gao C et al. A Comprehensive Analysis of Common and Rare Variants to Identify Adiposity Loci in Hispanic Americans: The IRAS Family Study (IRASFS). *PLoS One* 10, e0134649 (2015).
14. Graff M et al. Genome-wide physical activity interactions in adiposity - A meta-analysis of 200,452 adults. *PLoS Genet* 13, e1006528 (2017).
15. Justice AE et al. Genome-wide meta-analysis of 241,258 adults accounting for smoking behaviour identifies novel loci for obesity traits. *Nat Commun* 8, 14977 (2017). [PubMed: 28443625]
16. Ng MCY et al. Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. *PLoS Genet* 13, e1006719 (2017).
17. Aschard H, Vilhjalmsdottir BJ, Joshi AD, Price AL & Kraft P Adjusting for heritable covariates can bias effect estimates in genome-wide association studies. *Am J Hum Genet* 96, 329–39 (2015). [PubMed: 25640676]
18. Day FR, Loh PR, Scott RA, Ong KK & Perry JR A Robust Example of Collider Bias in a Genetic Association Study. *Am J Hum Genet* 98, 392–3 (2016). [PubMed: 26849114]
19. Feng S, Liu D, Zhan X, Wing MK & Abecasis GR RAREMETAL: fast and powerful meta-analysis for rare variants. *Bioinformatics* 30, 2828–9 (2014). [PubMed: 24894501]
20. Pers TH et al. Biological interpretation of genome-wide association studies using predicted gene functions. *Nat Commun* 6, 5890 (2015). [PubMed: 25597830]
21. Marouli E et al. Rare and low-frequency coding variants alter human adult height. *Nature* 542, 186–190 (2017). [PubMed: 28146470]
22. Lamparter D, Marbach D, Rueedi R, Kutalik Z & Bergmann S Fast and Rigorous Computation of Gene and Pathway Scores from SNP-Based Summary Statistics. *PLoS Comput Biol* 12, e1004714 (2016).
23. Locke AE et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 518, 197–206 (2015). [PubMed: 25673413]
24. Kawai M, de Paula FJ & Rosen CJ New insights into osteoporosis: the bone-fat connection. *J Intern Med* 272, 317–29 (2012). [PubMed: 22702419]
25. Turcot V et al. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. *Nat Genet* 50, 26–41 (2018). [PubMed: 29273807]
26. Liu DJ et al. Exome-wide association study of plasma lipids in >300,000 individuals. *PLoS Genet* 13, e1005378 (2017).
27. Kraja AT et al. New Blood Pressure-Associated Loci Identified in Meta-Analyses of 475 000 Individuals. *Circ Cardiovasc Genet* 10(2017).
28. Mahajan A et al. Identification and functional characterization of G6PC2 coding variants influencing glycaemic traits define an effector transcript at the G6PC2-ABCB11 locus. *PLoS Genet* 11, e1004876 (2015).
29. Manning A et al. A Low-Frequency Inactivating AKT2 Variant Enriched in the Finnish Population Is Associated With Fasting Insulin Levels and Type 2 Diabetes Risk. *Diabetes* 66, 2019–2032 (2017). [PubMed: 28341696]
30. Zhao W et al. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. *PLoS Genet* 13, e1005378 (2017).

31. Morris AP et al. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. *Nat Genet* 44, 981–90 (2012). [PubMed: 22885922]
32. Ng MC et al. Meta-analysis of genome-wide association studies in African Americans provides insights into the genetic architecture of type 2 diabetes. *PLoS Genet* 10, e1004517 (2014).
33. Mahajan A et al. Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. *Nat Genet* 46, 234–44 (2014). [PubMed: 24509480]
34. Saxena R et al. Genome-wide association study identifies a novel locus contributing to type 2 diabetes susceptibility in Sikhs of Punjabi origin from India. *Diabetes* 62, 1746–55 (2013). [PubMed: 23300278]
35. Cook JP & Morris AP Multi-ethnic genome-wide association study identifies novel locus for type 2 diabetes susceptibility. *Eur J Hum Genet* 24, 1175–80 (2016). [PubMed: 27189021]
36. Voight BF et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. *Nat Genet* 42, 579–89 (2010). [PubMed: 20581827]
37. Burdett T et al. The NHGRI-EBI Catalog of published genome-wide association studies. v1.0 edn Vol. 2015 (2015).
38. Hindorff LA et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. *Proc Natl Acad Sci U S A* 106, 9362–7 (2009). [PubMed: 19474294]
39. Lutoslawska G et al. Relationship between the percentage of body fat and surrogate indices of fatness in male and female Polish active and sedentary students. *J Physiol Anthropol* 33, 10 (2014). [PubMed: 24887103]
40. Verma M, Rajput M, Sahoo SS, Kaur N & Rohilla R Correlation between the percentage of body fat and surrogate indices of obesity among adult population in rural block of Haryana. *J Family Med Prim Care* 5, 154–9 (2016). [PubMed: 27453862]
41. Pereira PF et al. [Measurements of location of body fat distribution: an assessment of colinearity with body mass, adiposity and stature in female adolescents]. *Rev Paul Pediatr* 33, 63–71 (2015). [PubMed: 25623729]
42. Lu Y et al. New loci for body fat percentage reveal link between adiposity and cardiometabolic disease risk. *Nat Commun* 7, 10495 (2016). [PubMed: 26833246]
43. Chambers JC et al. Common genetic variation near MC4R is associated with waist circumference and insulin resistance. *Nat Genet* 40, 716–8 (2008). [PubMed: 18454146]
44. Nead KT et al. Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. *Hum Mol Genet* 24, 3582–94 (2015). [PubMed: 25784503]
45. Pospisilik JA et al. Drosophila genome-wide obesity screen reveals hedgehog as a determinant of brown versus white adipose cell fate. *Cell* 140, 148–60 (2010). [PubMed: 20074523]
46. Consortium GT Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* 348, 648–60 (2015). [PubMed: 25954001]
47. Baraille F, Planchais J, Dentin R, Guilmeau S & Postic C Integration of ChREBP-Mediated Glucose Sensing into Whole Body Metabolism. *Physiology (Bethesda)* 30, 428–37 (2015). [PubMed: 26525342]
48. Kursawe R et al. Decreased transcription of ChREBP-alpha/beta isoforms in abdominal subcutaneous adipose tissue of obese adolescents with prediabetes or early type 2 diabetes: associations with insulin resistance and hyperglycemia. *Diabetes* 62, 837–44 (2013). [PubMed: 23209190]
49. Lotta LA et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. *Nat Genet* 49, 17–26 (2017). [PubMed: 27841877]
50. Cargill M et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. *Am J Hum Genet* 80, 273–90 (2007). [PubMed: 17236132]
51. Hazlett J, Stamp LK, Merriman T, Highton J & Hessian PA IL-23R rs11209026 polymorphism modulates IL-17A expression in patients with rheumatoid arthritis. *Genes Immun* 13, 282–7 (2012). [PubMed: 22130325]

52. Karaderi T et al. Association between the interleukin 23 receptor and ankylosing spondylitis is confirmed by a new UK case-control study and meta-analysis of published series. *Rheumatology (Oxford)* 48, 386–9 (2009). [PubMed: 19189980]
53. Duerr RH et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. *Science* 314, 1461–3 (2006). [PubMed: 17068223]
54. Abdollahi E, Tavasolian F, Momtazi-Borojeni AA, Samadi M & Rafatpanah H Protective role of R381Q (rs11209026) polymorphism in IL-23R gene in immune-mediated diseases: A comprehensive review. *J Immunotoxicol* 13, 286–300 (2016). [PubMed: 27043356]
55. Abraham C, Dulai PS, Vermeire S & Sandborn WJ Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. *Gastroenterology* 152, 374–388 e4 (2017). [PubMed: 27780712]
56. Molinelli E, Campanati A, Ganzetti G & Offidani A Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts. *Curr Drug Saf* 11, 35–43 (2016). [PubMed: 26463248]
57. Fuchsberger C et al. The genetic architecture of type 2 diabetes. *Nature* 536, 41–7 (2016). [PubMed: 27398621]
58. Wells JC Sexual dimorphism of body composition. *Best Pract Res Clin Endocrinol Metab* 21, 415–30 (2007). [PubMed: 17875489]
59. Loomba-Albrecht LA & Styne DM Effect of puberty on body composition. *Curr Opin Endocrinol Diabetes Obes* 16, 10–5 (2009). [PubMed: 19115520]
60. Rogol AD, Roemmich JN & Clark PA Growth at puberty. *J Adolesc Health* 31, 192–200 (2002). [PubMed: 12470915]
61. Gibson G Rare and common variants: twenty arguments. *Nat Rev Genet* 13, 135–45 (2012). [PubMed: 22251874]
62. Stern JH, Rutkowski JM & Scherer PE Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. *Cell Metab* 23, 770–84 (2016). [PubMed: 27166942]
63. Dewey FE et al. Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease. *N Engl J Med* 374, 1123–33 (2016). [PubMed: 26933753]
64. Bondestam J et al. cDNA cloning, expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7 (ACVR1C). *Cytogenet Cell Genet* 95, 157–62 (2001). [PubMed: 12063393]
65. Jornvall H, Blokzijl A, ten Dijke P & Ibanez CF The orphan receptor serine/threonine kinase ALK7 signals arrest of proliferation and morphological differentiation in a neuronal cell line. *J Biol Chem* 276, 5140–6 (2001). [PubMed: 11084022]
66. Kim BC et al. Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells. *J Biol Chem* 279, 28458–65 (2004). [PubMed: 15107418]
67. Watanabe R et al. The MH1 domains of smad2 and smad3 are involved in the regulation of the ALK7 signals. *Biochem Biophys Res Commun* 254, 707–12 (1999). [PubMed: 9920806]
68. Kogame M et al. ALK7 is a novel marker for adipocyte differentiation. *J Med Invest* 53, 238–45 (2006). [PubMed: 16953060]
69. Murakami M et al. Expression of activin receptor-like kinase 7 in adipose tissues. *Biochem Genet* 51, 202–10 (2013). [PubMed: 23264230]
70. Carlsson LM et al. ALK7 expression is specific for adipose tissue, reduced in obesity and correlates to factors implicated in metabolic disease. *Biochem Biophys Res Commun* 382, 309–14 (2009). [PubMed: 19275893]
71. Carithers LJ & Moore HM The Genotype-Tissue Expression (GTEx) Project. *Biopreserv Biobank* 13, 307–8 (2015). [PubMed: 26484569]
72. Yogosawa S, Mizutani S, Ogawa Y & Izumi T Activin receptor-like kinase 7 suppresses lipolysis to accumulate fat in obesity through downregulation of peroxisome proliferator-activated receptor gamma and C/EBPalpha. *Diabetes* 62, 115–23 (2013). [PubMed: 22933117]

73. Yogosawa S & Izumi T Roles of activin receptor-like kinase 7 signaling and its target, peroxisome proliferator-activated receptor gamma, in lean and obese adipocytes. *Adipocyte* 2, 246–50 (2013). [PubMed: 24052900]
74. Seifi M, Ghasemi A, Namipashaki A & Samadikuchaksaraei A Is C771G polymorphism of MLX interacting protein-like (MLXIPL) gene a novel genetic risk factor for non-alcoholic fatty liver disease? *Cell Mol Biol (Noisy-le-grand)* 60, 37–42 (2014).
75. Cairo S, Merla G, Urbinati F, Ballabio A & Reymond A WBSR14, a gene mapping to the Williams--Beuren syndrome deleted region, is a new member of the Mlx transcription factor network. *Hum Mol Genet* 10, 617–27 (2001). [PubMed: 11230181]
76. Ambele MA, Dessels C, Durandt C & Pepper MS Genome-wide analysis of gene expression during adipogenesis in human adipose-derived stromal cells reveals novel patterns of gene expression during adipocyte differentiation. *Stem Cell Res* 16, 725–34 (2016). [PubMed: 27108396]
77. Marchler-Bauer A et al. CDD: NCBI's conserved domain database. *Nucleic Acids Res* 43, D222–6 (2015). [PubMed: 25414356]
78. Toyofuku T et al. Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. *EMBO J* 26, 1373–84 (2007). [PubMed: 17318185]
79. Gitler AD, Lu MM & Epstein JA PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. *Dev Cell* 7, 107–16 (2004). [PubMed: 15239958]
80. Luchino J et al. Semaphorin 3E suppresses tumor cell death triggered by the plexin D1 dependence receptor in metastatic breast cancers. *Cancer Cell* 24, 673–85 (2013). [PubMed: 24139859]
81. Shimizu I et al. Semaphorin3E-induced inflammation contributes to insulin resistance in dietary obesity. *Cell Metab* 18, 491–504 (2013). [PubMed: 24093674]
82. Verzijl HT, van der Zwaag B, Cruysberg JR & Padberg GW Mobius syndrome redefined: a syndrome of rhombencephalic maldevelopment. *Neurology* 61, 327–33 (2003). [PubMed: 12913192]
83. Verzijl HT, van der Zwaag B, Lammens M, ten Donkelaar HJ & Padberg GW The neuropathology of hereditary congenital facial palsy vs Mobius syndrome. *Neurology* 64, 649–53 (2005). [PubMed: 15728286]
84. Fujita M, Reinhart F & Neutra M Convergence of apical and basolateral endocytic pathways at apical late endosomes in absorptive cells of suckling rat ileum in vivo. *J Cell Sci* 97 (Pt 2), 385–94 (1990). [PubMed: 2277098]
85. Briegel W Neuropsychiatric findings of Mobius sequence -- a review. *Clin Genet* 70, 91–7 (2006). [PubMed: 16879188]
86. Ta-Shma A et al. Isolated truncus arteriosus associated with a mutation in the plexin-D1 gene. *Am J Med Genet A* 161A, 3115–20 (2013). [PubMed: 24254849]
87. Mazzotta C et al. Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. *Arthritis Res Ther* 17, 221 (2015). [PubMed: 26292963]
88. Yang WJ et al. Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis. *EMBO Mol Med* 7, 1267–84 (2015). [PubMed: 26194913]
89. Zygmunt T et al. Semaphorin-PlexinD1 signaling limits angiogenic potential via the VEGF decoy receptor sFlt1. *Dev Cell* 21, 301–14 (2011). [PubMed: 21802375]
90. Kim J, Oh WJ, Gaiano N, Yoshida Y & Gu C Semaphorin 3E-Plexin-D1 signaling regulates VEGF function in developmental angiogenesis via a feedback mechanism. *Genes Dev* 25, 1399–411 (2011). [PubMed: 21724832]
91. Bertolino P et al. Activin B receptor ALK7 is a negative regulator of pancreatic beta-cell function. *Proc Natl Acad Sci U S A* 105, 7246–51 (2008). [PubMed: 18480258]
92. Haworth KE et al. Methylation of the FGFR2 gene is associated with high birth weight centile in humans. *Epigenomics* 6, 477–91 (2014). [PubMed: 25431941]
93. Chi X et al. Angiopoietin-like 4 Modifies the Interactions between Lipoprotein Lipase and Its Endothelial Cell Transporter GPIHBP1. *J Biol Chem* 290, 11865–77 (2015). [PubMed: 25809481]
94. Catoire M et al. Fatty acid-inducible ANGPTL4 governs lipid metabolic response to exercise. *Proc Natl Acad Sci U S A* 111, E1043–52 (2014). [PubMed: 24591600]

95. van Raalte DH et al. Angiotensin-like protein 4 is differentially regulated by glucocorticoids and insulin in vitro and in vivo in healthy humans. *Exp Clin Endocrinol Diabetes* 120, 598–603 (2012). [PubMed: 22972030]
96. Koster A et al. Transgenic angiotensin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. *Endocrinology* 146, 4943–50 (2005). [PubMed: 16081640]
97. Thiagalingam A et al. RREB-1, a novel zinc finger protein, is involved in the differentiation response to Ras in human medullary thyroid carcinomas. *Mol Cell Biol* 16, 5335–45 (1996). [PubMed: 8816445]
98. Bonomo JA et al. The ras responsive transcription factor RREB1 is a novel candidate gene for type 2 diabetes associated end-stage kidney disease. *Hum Mol Genet* 23, 6441–7 (2014). [PubMed: 25027322]
99. Thiagalingam A, Lengauer C, Baylin SB & Nelkin BD RREB1, a ras responsive element binding protein, maps to human chromosome 6p25. *Genomics* 45, 630–2 (1997). [PubMed: 9367691]
100. Bisogno T et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. *J Cell Biol* 163, 463–8 (2003). [PubMed: 14610053]
101. Global Lipids Genetics, C. et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet* 45, 1274–83 (2013). [PubMed: 24097068]
102. Kooner JS et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. *Nat Genet* 40, 149–51 (2008). [PubMed: 18193046]
103. Pan LA et al. G771C Polymorphism in the MLXIPL Gene Is Associated with a Risk of Coronary Artery Disease in the Chinese: A Case-Control Study. *Cardiology* 114, 174–8 (2009). [PubMed: 19571538]
104. Kang G, Leech CA, Chepurny OG, Coetzee WA & Holz GG Role of the cAMP sensor Epac as a determinant of KATP channel ATP sensitivity in human pancreatic beta-cells and rat INS-1 cells. *J Physiol* 586, 1307–19 (2008). [PubMed: 18202100]
105. Ji Z, Mei FC & Cheng X Epac, not PKA catalytic subunit, is required for 3T3-L1 preadipocyte differentiation. *Front Biosci (Elite Ed)* 2, 392–8 (2010). [PubMed: 20036887]
106. Martini CN, Plaza MV & Vila Mdel C PKA-dependent and independent cAMP signaling in 3T3-L1 fibroblasts differentiation. *Mol Cell Endocrinol* 298, 42–7 (2009). [PubMed: 19010385]
107. Petersen RK et al. Cyclic AMP (cAMP)-mediated stimulation of adipocyte differentiation requires the synergistic action of Epac- and cAMP-dependent protein kinase-dependent processes. *Mol Cell Biol* 28, 3804–16 (2008). [PubMed: 18391018]
108. Yan J et al. Enhanced leptin sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking exchange protein directly activated by cyclic AMP isoform 1. *Mol Cell Biol* 33, 918–26 (2013). [PubMed: 23263987]
109. Gesta S et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. *Proc Natl Acad Sci U S A* 103, 6676–81 (2006). [PubMed: 16617105]
110. Gesta S et al. Mesodermal developmental gene Tbx15 impairs adipocyte differentiation and mitochondrial respiration. *Proc Natl Acad Sci U S A* 108, 2771–6 (2011). [PubMed: 21282637]
111. Lee KY et al. Tbx15 controls skeletal muscle fibre-type determination and muscle metabolism. *Nat Commun* 6, 8054 (2015). [PubMed: 26299309]

REFERENCES – ONLINE METHODS ONLY

112. Sudlow C et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med* 12, e1001779 (2015).
113. Liu DJ et al. Meta-analysis of gene-level tests for rare variant association. *Nat Genet* 46, 200–4 (2014). [PubMed: 24336170]
114. Goldstein JI et al. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. *Bioinformatics* 28, 2543–5 (2012). [PubMed: 22843986]
115. Winkler TW et al. Quality control and conduct of genome-wide association meta-analyses. *Nat Protoc* 9, 1192–212 (2014). [PubMed: 24762786]

116. Winkler TW et al. EasyStrata: evaluation and visualization of stratified genome-wide association meta-analysis data. *Bioinformatics* 31, 259–61 (2015). [PubMed: 25260699]
117. Purcell SM et al. A polygenic burden of rare disruptive mutations in schizophrenia. *Nature* 506, 185–90 (2014). [PubMed: 24463508]
118. Yang J et al. Genomic inflation factors under polygenic inheritance. *Eur J Hum Genet* 19, 807–12 (2011). [PubMed: 21407268]
119. Yang J et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 44, 369–75, S1–3 (2012). [PubMed: 22426310]
120. Marchini J, Howie B, Myers S, McVean G & Donnelly P A new multipoint method for genome-wide association studies by imputation of genotypes. *Nat Genet* 39, 906–13 (2007). [PubMed: 17572673]
121. Wellcome Trust Case Control, C. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 447, 661–78 (2007). [PubMed: 17554300]
122. Marchini J & Howie B Genotype imputation for genome-wide association studies. *Nat Rev Genet* 11, 499–511 (2010). [PubMed: 20517342]
123. Frey BJ & Dueck D Clustering by passing messages between data points. *Science* 315, 972–6 (2007). [PubMed: 17218491]
124. Moayyeri A, Hammond CJ, Valdes AM & Spector TD Cohort Profile: TwinsUK and healthy ageing twin study. *Int J Epidemiol* 42, 76–85 (2013). [PubMed: 22253318]
125. Boyd A et al. Cohort Profile: the ‘children of the 90s’--the index offspring of the Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* 42, 111–27 (2013). [PubMed: 22507743]
126. Kutalik Z, Whittaker J, Waterworth D, Beckmann JS & Bergmann S Novel method to estimate the phenotypic variation explained by genome-wide association studies reveals large fraction of the missing heritability. *Genet Epidemiol* 35, 341–9 (2011). [PubMed: 21465548]
127. Billingsley P *Probability and measure*, xii, 622 p. (Wiley, New York, 1986).
128. Surendran P et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension. *Nat Genet* 48, 1151–61 (2016). [PubMed: 27618447]
129. Nikpay M et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet* 47, 1121–30 (2015). [PubMed: 26343387]
130. Storey JD & Tibshirani R Statistical significance for genomewide studies. *Proc Natl Acad Sci U S A* 100, 9440–5 (2003). [PubMed: 12883005]
131. Civelek M et al. Genetic Regulation of Adipose Gene Expression and Cardio-Metabolic Traits. *Am J Hum Genet* 100, 428–443 (2017). [PubMed: 28257690]

Box 1.**Genes of biological interest harboring WHR-associated variants**

PLXND1– (3:129284818, rs2625973, known locus) The major allele of a common non-synonymous variant in Plexin D1 (L1412V, MAF = 26.7%) is associated with increased WHRadjBMI (β (SE)= 0.0156 (0.0024), P -value = 9.16×10^{-11}). *PLXND1* encodes a semaphorin class 3 and 4 receptor gene, and therefore, is involved in cell to cell signaling and regulation of growth in development for a number of different cell and tissue types, including those in the cardiovascular system, skeleton, kidneys, and the central nervous system^{77–81}. Mutations in this gene are associated with Moebius syndrome^{82–85}, and persistent truncus arteriosus^{79,86}. *PLXND1* is involved in angiogenesis as part of the SEMA and VEGF signalling pathways^{87–90}. *PLXND1* was implicated in the development of T2D through its interaction with *SEMA3E* in mice. *SEMA3E* and *PLXND1* are upregulated in adipose tissue in response to diet-induced obesity, creating a cascade of adipose inflammation, insulin resistance, and diabetes mellitus⁸¹. *PLXND1* is highly expressed in adipose (both subcutaneous and visceral) (GTEx). *PLXND1* is highly intolerant of mutations and therefore highly conserved (Supplementary Data 16). Last, our lead variant is predicted as damaging or possibly damaging for all algorithms examined (SIFT, Polyphen2/HDIV, Polyphen2/HVAR, LRT, MutationTaster).

ACVVIC– (2:158412701, rs55920843, novel locus) The major allele of a low frequency non-synonymous variant in activin A receptor type 1C (rs55920843, N150H, MAF = 1.1%) is associated with increased WHRadjBMI (β (SE)= 0.0652 (0.0105), P -value = 4.81×10^{-10}). *ACVVIC*, also called Activin receptor-like kinase 7 (*ALK7*), encodes a type I receptor for TGF β (Transforming Growth Factor, Beta-1), and is integral for the activation of SMAD transcription factors; therefore, *ACVVIC* plays an important role in cellular growth and differentiation^{64–68}, including adipocytes⁶⁸. Mouse *Acvr1c* decreases secretion of insulin and is involved in lipid storage^{69,72,73,69,72,73,91}. *ACVVIC* exhibits the highest expression in adipose tissue, but is also highly expressed in the brain (GTEx)^{69–71}. Expression is associated with body fat, carbohydrate metabolism and lipids in both obese and lean individuals⁷⁰. *ACVVIC* is moderately tolerant of mutations (ExAC Constraint Scores: synonymous = -0.86, nonsynonymous = 1.25, LoF = 0.04, Supplementary Data 16). Last, our lead variant is predicted as damaging for two of five algorithms examined (LRT and MutationTaster).

FGFR2– (10:123279643, rs138315382, novel locus) The minor allele of a rare synonymous variant in Fibroblast Growth Factor Receptor 2 (rs138315382, MAF=0.09%) is associated with increased WHRadjBMI (β (SE) = 0.258 (0.049), P -value = 1.38×10^{-07}). The extracellular portion of the FGFR2 protein binds with fibroblast growth factors, influencing mitogenesis and differentiation. Mutations in this gene have been associated with many rare monogenic disorders, including skeletal deformities, craniosynostosis, eye abnormalities, and LADD syndrome, as well as several cancers including breast, lung, and gastric cancer. Methylation of *FGFR2* is associated with high birth weight percentile⁹². *FGFR2* is tolerant of synonymous mutations, but highly intolerant of missense and loss-of-function mutations (ExAC Constraint scores:

synonymous = -0.9, missense = 2.74, LoF=1.0, Supplementary Data 16)). Last, this variant is not predicted to be damaging based on any of the five algorithms tested.

ANGPTL4– (19:8429323, rs116843064, novel locus) The major allele of a nonsynonymous low frequency variant in Angiopoietin Like 4 (rs116843064, E40K, EAF=98.1%) is associated with increased WHRadjBMI (β (SE) = 0.064 (0.011) P -value = 1.20×10^{-09}). *ANGPTL4* encodes a glycosylated, secreted protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators and functions as a serum hormone that regulates glucose homeostasis, triglyceride metabolism^{93,94}, and insulin sensitivity⁹⁵. *Angptl4*-deficient mice have hypotriglyceridemia and increased lipoprotein lipase (LPL) activity, while transgenic mice overexpressing *Angptl4* in the liver have higher plasma triglyceride levels and decreased LPL activity⁹⁶. The major allele of rs116843064 has been previously associated with increased risk of coronary heart disease and increased triglycerides⁶³. *ANGPTL4* is moderately tolerant of mutations (ExAC constraint scores synonymous = 1.18, missense = 0.21, LoF = 0.0, Supplementary Data 16). Last, our lead variant is predicted damaging for four of five algorithms (SIFT, Polyphen 2/HDIV, Polyphen2/HVAR, and MutationTaster).

RREB1– (6:7211818, rs1334576, novel association signal) The major allele of a common non-synonymous variant in the Ras responsive element binding protein 1 (rs1334576, G195R, EAF = 56%) is associated with increased WHRadjBMI (β (SE) = 0.017 (0.002), P -value = 3.9×10^{-15}). This variant is independent of the previously reported GWAS signal in the *RREB1* region (rs1294410; 6:6738752¹⁰). The protein encoded by this gene is a zinc finger transcription factor that binds to RAS-responsive elements (RREs) of gene promoters. It has been shown that the calcitonin gene promoter contains an RRE and

PLXND1– (3:129284818, rs2625973, known locus) The major allele of a common non-synonymous variant in Plexin D1 (L1412V, MAF = 26.7%) is associated with increased WHRadjBMI (β (SE)= 0.0156 (0.0024), P -value = 9.16×10^{-11}). *PLXND1* encodes a semaphorin class 3 and 4 receptor gene, and therefore, is involved in cell to cell signaling and regulation of growth in development for a number of different cell and tissue types, including those in the cardiovascular system, skeleton, kidneys, and the central nervous system^{77–81}. Mutations in this gene are associated with Moebius syndrome^{82–85}, and persistent truncus arteriosus^{79,86}. *PLXND1* is involved in angiogenesis as part of the SEMA and VEGF signalling pathways^{87–90}. *PLXND1* was implicated in the development of T2D through its interaction with *SEMA3E* in mice. *SEMA3E* and *PLXND1* are upregulated in adipose tissue in response to diet-induced obesity, creating a cascade of adipose inflammation, insulin resistance, and diabetes mellitus⁸¹. *PLXND1* is highly expressed in adipose (both subcutaneous and visceral) (GTEx). *PLXND1* is highly intolerant of mutations and therefore highly conserved (Supplementary Data 16)). Last, our lead variant is predicted as damaging or possibly damaging for all algorithms examined (SIFT, Polyphen2/HDIV, Polyphen2/HVAR, LRT, MutationTaster).

ACVR1C– (2:158412701, rs55920843, novel locus) The major allele of a low frequency non-synonymous variant in activin A receptor type 1C (rs55920843, N150H, MAF =

1.1%) is associated with increased WHRadjBMI (β (SE)= 0.0652 (0.0105), P -value = 4.81×10^{-10}). *ACVR1C*, also called Activin receptor-like kinase 7 (*ALK7*), encodes a type I receptor for TGF β (Transforming Growth Factor, Beta-1), and is integral for the activation of SMAD transcription factors; therefore, *ACVR1C* plays an important role in cellular growth and differentiation^{64–68}, including adipocytes⁶⁸. Mouse *Acvr1c* decreases secretion of insulin and is involved in lipid storage^{69,72,73,69,72,73,91}. *ACVR1C* exhibits the highest expression in adipose tissue, but is also highly expressed in the brain (GTEx)^{69–71}. Expression is associated with body fat, carbohydrate metabolism and lipids in both obese and lean individuals⁷⁰. *ACVR1C* is moderately tolerant of mutations (ExAC Constraint Scores: synonymous = -0.86, nonsynonymous = 1.25, LoF = 0.04, Supplementary Data 16). Last, our lead variant is predicted as damaging for two of five algorithms examined (LRT and MutationTaster).

FGFR2– (10:123279643, rs138315382, novel locus) The minor allele of a rare synonymous variant in Fibroblast Growth Factor Receptor 2 (rs138315382, MAF=0.09%) is associated with increased WHRadjBMI (β (SE) = 0.258 (0.049), P -value = 1.38×10^{-07}). The extracellular portion of the *FGFR2* protein binds with fibroblast growth factors, influencing mitogenesis and differentiation. Mutations in this gene have been associated with many rare monogenic disorders, including skeletal deformities, craniosynostosis, eye abnormalities, and LADD syndrome, as well as several cancers including breast, lung, and gastric cancer. Methylation of *FGFR2* is associated with high birth weight percentile⁹². *FGFR2* is tolerant of synonymous mutations, but highly intolerant of missense and loss-of-function mutations (ExAC Constraint scores: synonymous = -0.9, missense = 2.74, LoF=1.0, Supplementary Data 16). Last, this variant is not predicted to be damaging based on any of the five algorithms tested.

ANGPTL4– (19:8429323, rs116843064, novel locus) The major allele of a nonsynonymous low frequency variant in Angiopoietin Like 4 (rs116843064, E40K, EAF=98.1%) is associated with increased WHRadjBMI (β (SE) = 0.064 (0.011) P -value = 1.20×10^{-09}). *ANGPTL4* encodes a glycosylated, secreted protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators and functions as a serum hormone that regulates glucose homeostasis, triglyceride metabolism^{93,94}, and insulin sensitivity⁹⁵. *Angptl4*-deficient mice have hypotriglyceridemia and increased lipoprotein lipase (LPL) activity, while transgenic mice overexpressing *Angptl4* in the liver have higher plasma triglyceride levels and decreased LPL activity⁹⁶. The major allele of rs116843064 has been previously associated with increased risk of coronary heart disease and increased triglycerides⁶³. *ANGPTL4* is moderately tolerant of mutations (ExAC constraint scores synonymous = 1.18, missense = 0.21, LoF = 0.0, Supplementary Data 16). Last, our lead variant is predicted damaging for four of five algorithms (SIFT, Polyphen 2/HDIV, Polyphen2/HVAR, and MutationTaster).

RREB1– (6:7211818, rs1334576, novel association signal) The major allele of a common non-synonymous variant in the Ras responsive element binding protein 1 (rs1334576, G195R, EAF = 56%) is associated with increased WHRadjBMI (β (SE) = 0.017 (0.002), P -value = 3.9×10^{-15}). This variant is independent of the previously reported GWAS signal in the *RREB1* region (rs1294410; 6:6738752¹⁰). The protein encoded by this gene

is a zinc finger transcription factor that binds to RAS-responsive elements (RREs) of gene promoters. It has been shown that the calcitonin gene promoter contains an RRE and that the encoded protein binds there and increases expression of calcitonin, which may be involved in Ras/Raf-mediated cell differentiation^{97–99}. The ras responsive transcription factor *RREB1* is a candidate gene for type 2 diabetes associated end-stage kidney disease⁹⁸. This variant is highly intolerant to loss of function (ExAC constraint score LoF = 1, Supplementary Data 16)).

DAGLB – (7:6449496, rs2303361, novel locus) The minor allele of a common non-synonymous variant (rs2303361, Q664R, MAF = 22%) in *DAGLB* (Diacylglycerol lipase beta) is associated with increased WHRadjBMI (β (SE) = 0.0136 (0.0025), *P*-value = 6.24×10^{-8}). *DAGLB* encodes a diacylglycerol (DAG) lipase that catalyzes the hydrolysis of DAG to 2-arachidonoyl-glycerol, the most abundant endocannabinoid in tissues. In the brain, DAGL activity is required for axonal growth during development and for retrograde synaptic signaling at mature synapses (2-AG)¹⁰⁰. The *DAGLB* variant, rs702485 (7:6449272, $r^2 = 0.306$ and $D' = 1$ with rs2303361) has been previously associated with high-density lipoprotein cholesterol (HDL) previously. Pathway analysis indicate a role in the triglyceride lipase activity pathway¹⁰¹. *DAGLB* is tolerant of synonymous mutations, but intolerant of missense and loss of function mutations (ExAC Constraint scores: synonymous = -0.76, missense = 1.07, LoF = 0.94, Supplementary Data 16)). Last, this variant is not predicted to be damaging by any of the algorithms tested.

MLXIPL (7:73012042, rs35332062 and 7:73020337, rs3812316, known locus) The major alleles of two common non-synonymous variants (A358V, MAF = 12%; Q241H, MAF = 12%) in *MLXIPL* (MLX interacting protein like) are associated with increased WHRadjBMI (β (SE) = 0.02 (0.0033), *P*-value = 1.78×10^{-9} ; β (SE) = 0.0213 (0.0034), *P*-value = 1.98×10^{-10}). These variants are in strong linkage disequilibrium ($r^2 = 1.00$, $D' = 1.00$, 1000 Genomes CEU). This gene encodes a basic helix-loop-helix leucine zipper transcription factor of the Myc/Max/Mad superfamily. This protein forms a heterodimeric complex and binds and activates carbohydrate response element (ChoRE) motifs in the promoters of triglyceride synthesis genes in a glucose-dependent manner^{74,75}. This gene is possibly involved in the growth hormone signaling pathway and lipid metabolism. The WHRadjBMI-associated variant rs3812316 in this gene has been associated with the risk of non-alcoholic fatty liver disease and coronary artery disease^{74,102,103}. Furthermore, Williams-Beuren syndrome (an autosomal dominant disorder characterized by short stature, abnormal weight gain, various cardiovascular defects, and mental retardation) is caused by a deletion of about 26 genes from the long arm of chromosome 7 including *MLXIPL*. *MLXIPL* is generally intolerant to variation, and therefore conserved (ExAC Constraint scores: synonymous = 0.48, missense = 1.16, LoF = 0.68, Supplementary Data 16)). Last, both variants reported here are predicted as possible or probably damaging by one of the algorithms tested (PolyPhen).

RAPGEF3 (12:48143315, rs145878042, novel locus) The major allele of a low frequency non-synonymous variant in Rap Guanine-Nucleotide-Exchange Factor (GEF) 3 (rs145878042, L300P, MAF = 1.1%) is associated with increased WHRadjBMI (β (SE) = 0.085 (0.010), *P*-value = 7.15×10^{-17}). *RAPGEF3* codes for an intracellular cAMP

sensor, also known as Epac (the Exchange Protein directly Activated by Cyclic AMP). Among its many known functions, RAPGEF3 regulates the ATP sensitivity of the KATP channel involved in insulin secretion¹⁰⁴, may be important in regulating adipocyte differentiation^{105–107}, plays an important role in regulating adiposity and energy balance¹⁰⁸. *RAPGEF3* is tolerant of mutations (ExAC Constraint Scores: synonymous = -0.47, nonsynonymous = 0.32, LoF = 0, Supplementary Data 16)). Last, our lead variant is predicted as damaging or possibly damaging for all five algorithms examined (SIFT, Polyphen2/HDIV, Polyphen2/HVAR, LRT, MutationTaster).

TBX15 (1:119427467, rs61730011, known locus) The major allele of a low frequency non-synonymous variant in T-box 15 (rs61730011, M460R, MAF = 4.3%) is associated with increased WHRadjBMI (β (SE) = 0.041(0.005)). T-box 15 (*TBX15*) encodes a developmental transcription factor expressed in adipose tissue, but with higher expression in visceral adipose tissue than in subcutaneous adipose tissue, and is strongly downregulated in overweight and obese individuals¹⁰⁹. *TBX15* negatively controls depot-specific adipocyte differentiation and function¹¹⁰ and regulates glycolytic myofiber identity and muscle metabolism¹¹¹. *TBX15* is moderately intolerant of mutations and therefore conserved (ExAC Constraint Scores: synonymous = 0.42, nonsynonymous = 0.65, LoF = 0.88, Supplementary Data 16)). Last, our lead variant is predicted as damaging or possibly damaging for four of five algorithms (Polyphen2/HDIV, Polyphen2/HVAR, LRT, MutationTaster).




Figure 1. Summary of meta-analysis study design and workflow.

Abbreviations: EUR- European, AFR- African, SAS- South Asian, EAS- East Asian, and HIS- Hispanic/Latino ancestry. * Novel variants include those that are >1MB from a previously published WHRadjBMIGWAS tag SNP. ‡ Independent (INDEP) includes variants that are nearby known WHRadjBMI GWAS tag variants, but were determined independent after conditional analysis.




Figure 2.

Minor allele frequency compared to estimated effect. This scatter plot displays the relationship between minor allele frequency (MAF) and the estimated effect (β) for each significant coding variant in our meta-analyses. All novel WHRadjBMI variants are highlighted in orange, and variants identified only in models that assume recessive inheritance are denoted by diamonds and only in sex-specific analyses by triangles. Eighty percent power was calculated based on the total sample size in the Stage 1+2 meta-analysis and $P = 2 \times 10^{-7}$. Estimated effects are shown in original units (cm/cm) calculated by using effect sizes in standard deviation (SD) units times SD of WHR in the ARIC study (sexes combined = 0.067, men = 0.052, women = 0.080). WHR; waist-to-hip ratio




Figure 3. Regional association plots for known loci with novel coding signals identified by conditional analyses. Point color reflects r^2 calculated from the ARIC dataset. In a) there are two independent variants in *RSPO3* and *KIAA0408*, based on results from the stage 1 All Ancestry women ($N = 180,131$ for *RSPO3* and $139,056$ for *KIAA0408*). In b) we have a variant in *RREB1* that is independent of the GWAS variant rs1294421, based on results from the stage 1 All Ancestry sex-combined individuals ($N = 319,090$).




Figure 4.

Heat maps showing DEPICT gene set enrichment results from the stage 1 All Ancestry sex-combined individuals ($N = 344,369$). For any given square, the color indicates how strongly the corresponding gene (x-axis) is predicted to belong to the reconstituted gene set (y-axis). This value is based on the gene's z-score for gene set inclusion in DEPICT's reconstituted gene sets, where red indicates a higher and blue a lower z-score. To visually reduce redundancy and increase clarity, we chose one representative "meta-gene set" for each group of highly correlated gene sets based on affinity propagation clustering (Online Methods, Supplementary Note). Heatmap intensity and DEPICT P-values (Supplementary Data 8–9) correspond to the most significantly enriched gene set within the meta-gene set. Annotations for the genes indicate (1) the minor allele frequency of the significant ExomeChip (EC) variant (blue; if multiple variants, the lowest-frequency variant was kept), (2) whether the variant's P -value reached array-wide significance ($< 2 \times 10^{-7}$) or suggestive significance ($< 5 \times 10^{-4}$) (shades of purple), (3) whether the variant was novel, overlapping "relaxed" GWAS signals from Shungin et al.¹⁰ (GWAS $P < 5 \times 10^{-4}$), or overlapping "stringent" GWAS signals (GWAS $P < 5 \times 10^{-8}$) (pink), and (4) whether the gene was included in the gene set enrichment analysis or excluded by filters (shades of brown/orange) (Online Methods, Supplementary Note). Annotations for the gene sets indicate if the meta-gene set was found significant (shades of green; FDR < 0.01 , < 0.05 , or not significant) in the DEPICT analysis of GWAS results from Shungin et al.¹⁰

Table 1.

Association results for Combined Sexes.

Association results based on an additive or recessive model for coding variants that met array-wide significance ($P < 2 \times 10^{-7}$) in the sex-combined meta-analyses.

Locus (+/-1 Mb of a given variant)	Chr:Position (GRCh37) ^b	rsID	EA	OA	Gene ^c	Amino Acid Change ^c	If locus is known, nearby (<1 MB) published variant(s) ^d	N	EA ^f	β^e	SE	P-value	P-value for Sex-heterogeneity ^f	Other Criteria For Sig ^h	
1	2:15882701	rs55920843	T	G	ACVR1C	-	N150H	-	455,526	0.989	0.065	0.011	4.8E-10	1.7E-07	G,C
2	3:50597092	rs1034405	G	A	C3orf18	-	A162V	-	455,424	0.135	0.016	0.003	1.9E-07	8.8E-01	
3	4:120528327	rs3733526	G	A	PDE5A	-	A41V	-	461,521	0.187	0.015	0.003	2.6E-08	5.2E-03	
4	6:26108117	rs146860658	T	C	HIST1H1T	-	A69T	-	217,995	0.001	0.229	0.042	4.3E-08	6.3E-01	S
5	7:6449496	rs2303361	C	T	DAGLB	-	Q664R	-	475,748	0.221	0.014	0.003	6.2E-08	3.4E-03	G
6	10:123279643	rs138315382	T	C	FGFR2	-	synonymous	-	236,962	0.001	0.258	0.049	1.4E-07	1.1E-01	G,S
7	11:65403651	rs7114037	C	A	PCNXL3	-	H1822Q	-	448,861	0.954	0.029	0.005	1.8E-08	4.4E-01	
8	12:48143315	rs145878042	A	G	RAPGEF3	-	L300P	-	470,513	0.990	0.085	0.010	7.2E-17	7.3E-03	
9	12:108618630	rs3764002	C	T	WSCD2	-	T266I	-	474,637	0.737	0.014	0.002	9.8E-10	5.5E-01	
10	15:42032383	rs17677991	G	C	MGA	-	P1523A	-	469,874	0.345	0.015	0.002	3.5E-11	9.1E-01	
11	16:4432029	rs3810818	A	C	VASN	-	E384A	-	424,163	0.231	0.016	0.003	2.0E-09	3.3E-01	
	16:4445327	rs3747579	C	T	CORO7	-	R193Q	-	453,078	0.299	0.018	0.002	2.2E-13	4.3E-02	
	16:4484396	rs1139653	A	T	DNAJA3	-	N75Y	-	434,331	0.284	0.015	0.002	4.3E-10	1.4E-01	
12	19:49232226	rs2287922	A	G	RASIP1	-	R601C	-	430,272	0.494	0.014	0.002	1.6E-09	3.7E-02	
	19:49244220	rs2307019	G	A	IZUMO1	-	A333V	-	476,147	0.558	0.012	0.002	4.7E-08	3.9E-02	
13	20:42965811	rs144098855	T	C	R3HDM1	-	P5L	-	428,768	0.001	0.172	0.032	9.7E-08	1.0E+00	G

Variants in Novel Loci

All Ancestry Additive model Sex-combined analyses

European Ancestry Additive model Sex-combined analyses

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

14	1:173802608	rs35515638	G	A	DARS2	K196R	-	352,646	0.001	0.201	0.038	1.4E-07	6.0E-02	G
15	14:58838668	rs1051860	A	G	ARID4A	synonymous	-	367,079	0.411	0.013	0.002	2.2E-08	1.3E-01	
16	15:42115747	rs3959569	C	G	MAPKBPI	R1240H	-	253,703	0.349	0.017	0.003	2.0E-08	6.3E-01	

Variants in Previously Identified Loci

All Ancestry Additive model Sex-combined analyses

1	1:119427467	rs61730011	A	C	TBX15	M566R		rs2645294, rs12731372, rs12143789, rs1106529	0.041	0.005	0.000	2.2E-14	6.7E-01	
	1:119469188	rs10494217	T	G		H156N			0.018	0.003	0.000	1.4E-10	6.0E-01	
2	1:154987704	rs141845046	C	T	ZBTB7B	P190S		rs905938	0.037	0.007	0.000	3.8E-08	7.9E-07	C
3	2:165551201	rs7607980	T	C	COBLL1	N941D		rs1128249, rs10195252, rs12692737, rs12692738, rs17185198	0.026	0.004	0.000	1.6E-13	3.0E-30	
4	2:188343497	rs7586970	T	C	TFPI	N221S		rs1569135	0.016	0.002	0.000	3.0E-12	6.3E-01	
5	3:52558008	rs13303	T	C	STAB1	M113T			0.019	0.002	0.000	5.5E-18	6.7E-02	
	3:52833805	rs3617	C	A	ITIH3	Q315K		rs2276824	0.015	0.002	0.000	1.6E-12	4.0E-01	C
6	3:129137188	rs62266958	C	T	EFCAB12	R197H			0.036	0.004	0.000	8.3E-17	9.3E-05	
	3:129284818	rs2625973	A	C	PLXND1	L1412V		rs10804591	0.016	0.002	0.000	9.2E-11	1.6E-05	
7	4:89625427	rs1804080	G	C	HERC3	E946Q			0.021	0.003	0.000	1.5E-12	4.1E-06	
	4:89668859	rs7657817	C	T	FAM13A	V443I		rs9991328	0.016	0.003	0.000	5.0E-09	9.6E-05	
8	5:176516631	rs1966265	A	G	FGFR4	V10I		rs6556301	0.023	0.003	0.000	1.7E-19	2.1E-01	
9	6:7211818	rs1334576 ^g	G	A	RREB1	G195R		rs1294410	0.017	0.002	0.000	3.9E-15	1.5E-01	
10	6:34827085	rs9469913	A	T	UHRF1BP1	Q984H			0.021	0.004	0.000	1.2E-08	2.7E-01	C
	6:127476516	rs1892172	A	G	RSPO3	synonymous		rs1776897	0.031	0.002	0.000	2.6E-47	7.7E-09	
11	6:127767954	rs139745911 ^g	A	G	KIAA0408	P504S		rs11961815, rs72959041, rs1936805	0.103	0.012	0.000	6.8E-19	2.0E-04	
	7:73012042	rs35332062	G	A	MLXIPL	A358V			0.020	0.003	0.000	1.8E-09	1.5E-01	
12	7:73020337	rs3812316	C	G		Q241H		rs6976930	0.021	0.003	0.000	2.0E-10	5.8E-02	
	10:95931087	rs17417407	T	G	PLCE1	R240L			0.173	0.003	0.000	2.5E-11	5.9E-01	
14	11:64031241	rs35169799	T	C	PLCB3	S778L		rs10786152	0.061	0.004	0.000	9.1E-15	1.3E-04	
	12:123444507	rs58843120	G	T	ABDB9	F92L			0.987	0.009	0.000	1.3E-08	3.5E-01	
15	12:124265687	rs11057353	T	C	DNAH10	S228P			0.373	0.002	0.000	2.1E-16	2.7E-08	
	12:124330311	rs34934281	C	T		T1785M		rs4765219, rs863750	0.025	0.003	0.000	2.9E-14	3.1E-08	
	12:124427306	rs11057401	T	A	CCDC92	S53C			0.029	0.002	0.000	7.3E-37	5.5E-11	

16	15:56756285	rs1715919	G	T	<i>MNS1</i>	Q55P	rs8030605	476,274	0.096	0.023	0.004	8.8E-11	2.7E-02
17	16:67397580	rs9922085	G	C	<i>LRRC36</i>	R101P	rs6499129	469,474	0.938	0.034	0.005	3.8E-13	5.9E-01
	16:67409180	rs8052655	G	A		G388S		474,035	0.939	0.034	0.005	5.5E-13	4.0E-01
18	19:18285944	rs11554159	A	G	<i>IFI30</i>	R76Q	rs12608504	476,389	0.257	0.015	0.002	3.5E-10	3.1E-03
	19:18304700	rs874628	G	A	<i>MPV17L2</i>	M72V		476,388	0.271	0.015	0.002	1.2E-10	2.5E-03
19	20:33971914	rs4911494	T	C	<i>UQCC1</i>	R51Q	rs224333	451,064	0.602	0.018	0.002	2.5E-16	1.5E-03
	20:34022387	rs224331	A	C	<i>GDF5</i>	S276A		345,805	0.644	0.017	0.003	1.8E-11	3.2E-03

All Ancestry Recessive model Sex-combined analyses

20	17:17425631	rs897453	C	T	<i>PEMT</i>	V58L	rs4646404	476,546	0.569	0.025	0.004	4.1E-11	8.2E-01
----	-------------	----------	---	---	-------------	------	-----------	---------	-------	-------	-------	----------------	---------

European Ancestry Additive model Sex-combined analyses

6	3:129293256	rs2255703	T	C	<i>PLXND1</i>	M870V	rs10804591	420,520	0.620	0.014	0.002	3.1E-09	1.6E-04
---	-------------	-----------	---	---	---------------	-------	------------	---------	-------	-------	-------	----------------	----------------

Abbreviations: GRCh37=human genome assembly build37;rsID=based on dbSNP; VEP=Ensembl Variant Effect Predictor toolset; GTEx=Genotype-Tissue Expression project;SD=standard deviation; SE=standard error;N=sample size; EAF=effect allele frequency; E.A=effect allele; O.A=other allele.

^aCoding variants refer to variants located in the exons and splicing junction regions.

^bVariant positions are reported according to Human assembly build 37 and their alleles are coded based on the positive strand.

^cThe gene the variant falls in and amino acid change from the most abundant coding transcript is shown (protein annotation is based on VEP toolset and transcript abundance from GTEx database).

^dPreviously published variants within +/-1Mb are from Shungin et al.¹⁰, except for rs6976930 and rs10786152 from Graff et al.¹⁴ and rs6499129 from Ng. et al 16.

^eEffect size is based on standard deviation (SD) per effect allele

^fP-value for sex heterogeneity, testing for difference between women-specific and men-specific beta estimates and standard errors, was calculated using EasyStrata: Winkler, T.W. et al. EasyStrata: evaluation and visualization of stratified genome-wide association meta-analysis data. Bioinformatics 2015; 31, 259–61.PMID: 25260699. Bolded P-values met significance threshold after bonferroni correction (P-value<7.14E-04; i.e. 0.05/70 variants).

^g**rs1334576 in RREB1** is a new signal in a known locus that is independent from the known signal, rs1294410; **rs139745911 in KIAA0408** is a new signal in a known locus that is independent from all known signals rs11961815, rs72959041, rs1936805, in a known locus (see Supplementary Table 4).

^hEach flag indicates a that a secondary criterion for significance may not be met, G- P-value > 5×10⁻⁸ (GWAS significant), C- Association Signal was not robust against collider bias; S- variant was not available in stage 2 studies for validation of Stage 1 association.

Table 2.

Association results for Sex-stratified analyses.

Association results based on an additive or recessive model for coding variants that met array-wide significance ($P < 2 \times 10^{-7}$) in the sex-specific meta-analyses and reach Bonferroni corrected P -value for sex heterogeneity ($P_{\text{sexhet}} < 7.14 \times 10^{-4}$).

Locus (+/-1Mb of a given variant)	Chr:Position (GRCh37) ^c	rsID	EA	OA	Gene ^d	Amino Acid Change ^d	In sex-combined analyses ^e	If locus is known, nearby (<1 MB) published variant(s) ^f	P-value for Sex-heterogeneity ^g	Men				Women				Other Criteria For Sig ^h		
										N	EAF	β	SE	P	N	EAF	β		SE	P
Variants in Novel Loci																				
All Ancestry Additive model Men only analyses																				
1	13:96656597	rs148108950	A	G	UGG72	P175L	No	-	1.5E-06	203,009	0.006	0.130	0.024	6.1E-08	221,300	0.004	-0.044	0.027	1.1E-01	G
2	14:23312594	rs1042704	A	G	MAMP14	D273N	No	-	2.6E-04	226,646	0.202	0.021	0.004	2.6E-08	250,018	0.197	0.002	0.004	6.1E-01	
All Ancestry Additive model Women only analyses																				
3	1:205130413	rs3851294	G	A	DSFYK	C641R	No	-	9.8E-08	225,803	0.914	-0.005	0.005	3.4E-01	249,471	0.912	0.034	0.005	4.5E-11	
4	2:158412701	rs55920843	T	G	ACVRLC	N150H	Yes	-	1.7E-07	210,071	0.989	0.006	0.015	7.2E-01	245,808	0.989	0.113	0.014	1.7E-15	
5	19:8429323	rs110843064	G	A	ANGPTL4	E40K	No	-	1.3E-07	203,098	0.981	-0.017	0.011	1.4E-01	243,351	0.981	0.064	0.011	1.2E-09	
Variants in Previously Identified Loci																				
All Ancestry Additive model Women only analyses																				
1	1:154987704	rs141845046	C	T	ZBTB7B	P190S	Yes	rs905938	7.9E-07	226,709	0.975	0.004	0.010	6.9E-01	250,084	0.977	0.070	0.010	2.3E-13	
2	2:165551201	rs7607980	T	C	COBLL1	N941D	Yes	rs1128249, rs10195252, rs12692737, rs12692738, rs17185198	3.0E-30	173,600	0.880	-0.018	0.005	5.8E-04	216,656	0.878	0.062	0.005	6.7E-39	
3	3:129137188	rs62266958	C	T	EFCAB12	R197H	Yes	rs10804591	9.3E-05	226,690	0.937	0.018	0.006	3.1E-03	250,045	0.936	0.051	0.006	8.1E-18	
	3:129284818	rs2625973	A	C	PLXND1	L1412V	Yes		1.6E-05	226,650	0.736	0.005	0.003	1.9E-01	250,023	0.730	0.025	0.003	8.2E-14	
	3:129293256	rs2255703	T	C	PLXND1	M870V	Yes		5.0E-04	226,681	0.609	0.003	0.003	3.1E-01	250,069	0.602	0.018	0.003	1.9E-09	
4	4:89625427	rs1804080	G	C	HERC3	E946Q	Yes	rs9991328	4.1E-06	222,556	0.839	0.008	0.004	6.6E-02	223,877	0.837	0.034	0.004	2.1E-16	
	4:89668859	rs7657817	C	T	FAM13A	V443I	Yes		9.6E-05	226,680	0.816	0.006	0.004	1.5E-01	242,970	0.815	0.026	0.004	5.9E-12	
5	6:127476516	rs1892172	A	G	RSP03	synonymous	Yes	rs11961815, rs72959041, rs1936805	7.7E-09	226,677	0.541	0.018	0.003	5.6E-10	250,034	0.545	0.042	0.003	3.4E-48	
	6:127767954	rs139745911	A	G	KIAA0408	P504S	Yes		2.0E-04	188,079	0.010	0.057	0.017	6.8E-04	205,203	0.010	0.143	0.016	5.9E-19	
6	11:64031241	rs35169799	T	C	PLCB3	S778L	Yes	rs11231693	1.3E-04	226,713	0.061	0.016	0.006	9.6E-03	250,097	0.061	0.049	0.006	6.7E-16	
	12:124265687	rs11057353	T	C	DNAH10	S228P	Yes		2.7E-08	226,659	0.370	0.005	0.003	8.3E-02	250,054	0.376	0.029	0.003	3.1E-22	
7	12:124330311	rs34934281	C	T		T1785M	Yes	rs4765219, rs863750	3.1E-08	226,682	0.891	0.006	0.005	1.9E-01	250,066	0.887	0.043	0.005	1.4E-20	
	12:124427306	rs11057401	T	A	CCDC92	S53C	Yes		5.5E-11	223,324	0.701	0.013	0.003	4.3E-05	244,678	0.689	0.043	0.003	1.0E-41	

Abbreviations: GRCh37=human genome assembly build 37;rsID=based on dbSNP; VEP=Ensembl Variant Effect Predictor toolset; CTEX=Genotype-Tissue Expression project; SD=standard deviation; SE=standard error;N=sample size; EA=effect allele; OA=other allele; EAF=effect allele frequency.

- ^aCoding variants refer to variants located in the exons and splicing junction regions.
- ^bBonferroni corrected Pvalue for the number of SNPs tested for sex-heterogeneity is $<7.14E-04$ i.e. $0.05/70$ variants.
- ^cVariant positions are reported according to Human assembly build 37 and their alleles are coded based on the positive strand.
- ^dThe gene the variant falls in and amino acid change from the most abundant coding transcript is shown (protein annotation is based on VEP toolset and transcript abundance from GTEx database).
- ^eVariant was also identified as array-wide significant in the sex-combined analyses.
- ^fPreviously published variants within +/-1Mb are from Shungin D et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature* 2015; 518, 187–196 doi:10.1038/nature14132 (PMID 25673412).
- ^gP-value for sex heterogeneity, testing for difference between women-specific and men-specific beta estimates and standard errors, was calculated using EasyStrata: Winkler, T.W. et al. EasyStrata: evaluation and visualization of stratified genome-wide association meta-analysis data. *Bioinformatics* 2015; 31, 259–61. PMID: 25260699.
- ^hEffect size is based on standard deviation (SD) per effect allele
- ⁱrs139745911 in KIAA0408 is a new signal in a known locus that is independent from all known signals rs11961815, rs72959041, rs1936805, in a known locus (see Supplementary 8A/B).
- ^jEach flag indicates a that a secondary criterion for significance may not be met, G- P-value $> 5 \times 10^{-8}$ (GWAS significant), C- Association Signal was not robust against collider bias; S- variant was not available in Stage 2 studies for validation of Stage 1 association.